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In memory of my Father 
 
 
 
 
 
 
 
 
 
"I was taught that the way of progress was neither swift nor easy." 
 
— Marie Curie, Physicist, Chemist, and winner of the 1903 Nobel Prize in Physics and 
the 1911 Nobel Prize in Chemistry 
 

  
POPULÄRVETENSKAPLIG SAMMANFATTNING  
Hjärt-kärlsjukdomar är bland de vanligaste och dödligaste sjukdomarna i världen. En av de 
viktigaste bakomliggande orsakerna till hjärt-kärlsjukdomar är åderförkalkning där blodkärlens 
väggar blir inflammerade och så kallade plack byggs upp av bl.a. kolesterolpartiklar från 
blodet. Plack utvecklas långsamt i artärerna och blir med tiden större och riskerar att täppa till 
kärlens blodflöde, vilket kan ge upphov till bland annat kärlkramp. Dessutom kan vissa plack 
innehålla mycket inflammatoriska celler vilket gör dem instabila med risk för att brista. Om 
placket brister bildas en blodpropp i hjärtats kranskärl eller i halskärlen som ger blodflöde till 
hjärnan, och symptom på hjärtinfarkt respektive stroke kan då uppträda. 
Forskningen syftar till att utveckla nya kontrastmedel för icke-invasiv avbildning av 
inflammation i sjukdomsprocesser, speciellt åderförkalkning och instabila inflammerade plack. 
Förhoppningen och strävan är att ett nytt skonsamt undersökningsalternativ som möjliggör 
tidigare diagnos av dessa tillstånd kan identifiera de patienter som behöver en invasiv eller 
specifik sorts behandling. 
Idén är att kontrastmedel eller molekylära prober, som består av stora molekyler eller 
mycket små partiklar, ska vara målsökande och hitta till specifika inflammatoriska 
cellmarkörer som finns på eller i instabila plack. För att uppnå en specifik målsökning krävs 
det att man känner till vilka markörer som är specifika för just de celler som är aktiva i en 
sjukdom och att man har strategier för att möjliggöra målsökning av dessa markörer. En sådan 
målsökning möjliggörs genom att man modifierar kontrastmedlets yta med exempelvis 
antikroppar mot den identifierade cellmarkören eller andra förändringar som gör att cellen 
känner igen kontrastmedlet. Ett fungerande kontrastmedel eller molekylär prob måste 
dessutom ha egenskaper som ger, eller förbättrar bilder som tas med en eller flera olika 
avbildningstekniker. Molekylen eller partikeln måste då bära på funktionella enheter som har 
minst en av dessa egenskaper.  
Totalt undersökte vi sju olika typer av molekylära prober i denna avhandling. I 
delarbete I och II bestod dessa av gasbubblor, av biokompatibelt material med olika 
funktionella egenskaper i skalet för bland annat ultraljud, nuklearmedicinsk och magnetisk 
resonansavbildning. I delarbete III-IV användes humant serum albumin som bärarmolekyl som 
modifierades för målsökning och för att ge upphov till signal med nuklearmedicinska tekniker. 
I delarbete II-IV modifierades dessa prober med antikroppar eller kemiska strukturer för 
målsökande avbildning av inflammation. De molekylära probernas egenskaper, 
upptagsmekanismer och tillämpbarhet för avbildning undersöktes i cell- och djurstudier.  
Forskningen som utförts inom ramen för denna avhandling är ett multidisciplinärt 
samarbete som involverar olika typer av naturvetenskapliga forskare. Avsikten var att kartlägga 
celler och specifika markörer involverade i åderförkalkning och att utveckla kontrastmedel som 
studeras i cell- och djurstudier för målsökning och avbildning med olika bildtekniker så som 
ultraljud, skiktröntgen, magnetkamera eller nuklearmedicinska tekniker. Målet för framtiden 
är att kunna bidra till den medicinvetenskapliga utvecklingen genom att detektera farlig 
åderförkalkning som kan motivera särskild behandling, vilket i slutändan gagnar patienten. 
ABSTRACT 
The imaging field is rapidly evolving and in the last two decades there have been tremendous 
developments in the field of multimodal imaging. Multimodal molecular imaging approaches 
that utilize ultrasound/magnetic resonance imaging (US/MRI), single-photon emission 
computed tomography/computed tomography (SPECT/CT), or positron emission 
tomography/MRI (PET/MRI) may provide additional detailed information at the cellular and 
molecular level to help identify patients with vulnerable plaques that are at risk of rupture. The 
search for specific biomarkers in combination with specific and optimized molecular probes 
may help to prevent adverse events such as myocardial infarctions or strokes. Current clinical 
contrast agents do not provide information on the inflammatory components of atherosclerotic 
plaques; thus, more specific molecular probes are needed. This thesis focuses on probe 
development for different molecular imaging techniques using multimodal and targeting 
approaches.  
Several types of molecular probe were evaluated: bimodal and multimodal 
microbubbles, as well as chemically modified human serum albumin (HSA)-based probes 
(aconitylated (Aco) and maleylated (Mal)) for targeting markers of inflammation; adhesion 
molecules on endothelial cells or macrophages, and scavenger receptor A1 (SR-A1) on 
macrophages. Evaluation of these molecular probes was facilitated by their physical properties 
enabling assessment with fluorescence microscopy, flow cytometry, and nuclear imaging 
properties for in vivo molecular imaging with SPECT/CT and PET/MRI.  
We found that functionalizing molecular probes with targeting moieties greatly 
improved the targeting specificity and avidity to the target compared to non-targeted molecular 
probes. Furthermore, these molecular probes were successfully radiolabeled with a detectable 
in vivo signal by 99mTc-anti-ICAM-1- MBs imaging of inflammation with SPETC/CT, and 
atherosclerosis by 89Zr-Mal-HSA with PET/MRI. Ex vivo evaluation of HSA-based probes 
showed significant accumulation in atherosclerotic lesions of Apoe-/- mice, as quantified by 
gamma counter and phosphor imaging autoradiography, compared to wild type (WT) mice.  
In conclusion, adhesion molecule targeting and scavenger receptor targeting with 
functionally modified probes in this thesis showed potential for the imaging of inflammation 
and atherosclerosis. Of the evaluated probes, modified HSA-based probes seem to have the 
greatest potential for clinical application in molecular imaging of atherosclerosis.  
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1 RATIONALE 
At present, despite significant diagnostic and therapeutic improvements, cardiovascular 
diseases (CVDs) account for the majority of deaths worldwide. Accurate diagnosis is important 
in giving the patient the right treatment at the right time. The challenging questions for 
cardiologists and vascular surgeons remain: How can one discover patients at risk of future 
symptomatic events from atherosclerotic lesions? Which patients should we screen, treat, and 
operate on? Today we are able to identify culprit lesions in the coronary arteries via gold 
standard angiography in symptomatic patients, but what about the subclinical disease burden 
and the “asymptomatic patients” with currently non-obstructive but potentially dangerous 
atherosclerosis? We know that some of these harbor features that will eventually cause the 
plaque to rupture, but there are insufficient diagnostic tools. In order to answer these questions, 
it is not uncommon for a patient to undergo several diagnostic examinations.  
In clinical practice, the lumenography approach using invasive angiography is still the 
backbone of imaging. However, the information provided is limited and insufficient to predict 
the likelihood of future thromboembolic events. The research field of molecular imaging has 
focused on developing noninvasive methods to improve the visualization of vulnerable plaque. 
A lot of research has also been dedicated to finding specific biomarkers to predict future events 
by screening patients or subjects in the general population. When combined with today’s rapid 
advances in the molecular imaging field using more specific molecular imaging probes, this 
might allow us to detect and visualize rupture-prone plaques. 
Nuclear imaging techniques in combination with anatomical imaging, such as 
computed tomography (CT) or magnetic resonance imaging (MRI), have emerged as 
promising tools due to their benefits in localizing targets with high sensitivity and molecular 
precision (Brinjikji et al. 2016; Tarkin et al. 2016). The most studied targets in atherosclerosis 
include microcalcification, neovascularization, macrophages, and adhesion molecules 
expressed on activated endothelium (Quillard et al. 2012; Sriranjan et al. 2016; Tarkin et al. 
2016). The most commonly utilized radiotracer in molecular imaging is fluorine-18 
fluorodeoxyglucose (18F-FDG) (Rudd et al. 2008; Rudd et al. 2009). However, the tracer has 
low specificity, which limits its use, and more specific probes for the imaging of inflammation 
in atherosclerosis are needed. Developing effective probes for this purpose is often difficult 
and is an area of intense research. Extensive in vitro and in vivo preclinical evaluation is needed 
before application to humans. This thesis focuses on the probe development and preclinical 
evaluation of probe-cell interactions in endothelial cells and macrophages as well as the 
feasibility of in vivo atherosclerotic plaque detection for application in molecular imaging of 
inflammation.   
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2 REVIEW OF LITERATURE 
2.1 Cardiovascular Diseases  
CVDs are the leading cause of global fatalities. Over 80% of all CVD deaths are due to 
myocardial infarctions and strokes (World Health Organization 2017). Myocardial infarction 
and ischemic stroke occur as a result of blockage of the blood vessels, giving rise to symptoms 
such as chest pain or neurological deficits. Established risk factors based on the Framingham 
heart study include unhealthy diet, tobacco use, inadequate physical activity, and inherited 
genetic factors. These factors may in turn lead to high blood glucose level (diabetes), 
hyperlipidemia, hypertension, and obesity, and increase the risk of cardiovascular events 
(Benjamin et al. 2018; Mahmood et al. 2014). The underlying cause in most cases is 
atherosclerosis, which is compartmentalized into coronary artery disease, carotid artery 
disease, and peripheral artery disease. Patients with atherosclerotic lesions may be classified as 
symptomatic or asymptomatic (Naghavi et al. 2003). Although so-called silent myocardial 
infarctions exist (Barbier et al. 2006), events are usually symptomatic. With carotid stenosis, 
indications of plaque vulnerability are more pronounced among symptomatic patients (Matic 
et al. 2018). Stenosis in the carotid or coronary arteries can be evaluated by computed 
tomography (CT) and, in the former case, also by ultrasound. However, both myocardial 
infarctions and strokes can occur as a result of atherosclerotic plaque rupture and subsequent 
thrombosis without a prior advanced arterial obstruction (Naghavi et al. 2003). 
Characterization of plaque vulnerability, or the vulnerable patient, is therefore important for 
the possibility of optimizing treatment and preventive measures in atherosclerosis on an 
individualized basis. 
Clinical management focuses on preventive strategies (primary, secondary, and tertiary), 
diagnostic strategies (screening, acute exams, and follow-ups), and medical treatment and 
interventions. To help guide clinicians, the European Society of Cardiology (ESC) ((ESC) 
2018) and the European Society of Vascular Surgery (ESVS) (Naylor et al. 2018; Powers et al. 
2018) have established guidelines and clinical algorithms by which patients’ conditions should 
be managed to prevent the first onset or recurrence of events and reduce mortality. 
Identification of patients at risk of cardiovascular events is crucial. Related research, focusing 
on basic scientific and diagnostic improvements—such as this thesis—is necessary to transfer 
the knowledge derived from preclinical research into clinical applications that benefit the 
patient.   
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2.2 Atherosclerosis 
2.2.1 The History of Atherosclerosis  
Leonardo Da Vinci was among the first to describe atherosclerosis (Davies et al. 1996). In the 
mid-eighteenth century one of the first cases of plaque rupture was reported: the Danish artist 
Bertil Thorvaldsen suffered a sudden cardiac arrest in the middle of a concert and the 
subsequent autopsy attributed coronary plaque rupture as the cause of death. At the end of the 
eighteenth century, two theories arose describing the pathophysiology of atherosclerosis: the 
thrombogenic theory proposed by Carl von Rokitansky and the inflammatory theory with in-
depth histological characterization of atherosclerotic lesions proposed by Rudolf Virchow. 
Virchow proposed a link between the thrombogenicity of the blood, the diseased vessel wall, 
and the resulting hemodynamics, which collectively caused thrombosis. These factors are 
termed Virchow’s triad. Virchow’s hypothesis of local intimal injury formed the basis of the 
response to injury hypothesis formulated by Ross and Glomset in the 1970s, describing smooth 
muscle cell proliferation as a response to injury (Ross et al. 1976a; Ross et al. 1976b). The 
release by endothelial cells of an endothelium relaxing factor, later identified as nitric oxide 
(NO) and crucial for vascular function, was proposed by Robert Furchgott, who shared the 
Nobel Prize in physiology or medicine with Ferid Murad and Louis Ignarro in 1998 (Rubin 
2019). Furthermore, in the 1990s, two other hypotheses were presented: one describing lipid 
retention as the major cause of atherogenesis (Watanabe et al. 1985; Williams et al. 1995) and 
the other describing inflammatory processes as the driving cause (Hansson et al. 2002). Intense 
research within the field, spearheaded by Libby’s, Hansson’s, and Fogelman’s groups, have 
led to an understanding of some of the underlying inflammatory mechanisms of atherosclerosis, 
involving cells from both the innate and adaptive immune systems, chemical factors, and local 
or systemic inflammation (Slijkhuis et al. 2009). Extensive research has also focused on the 
detection of inflammatory biomarkers as a sign of unstable disease (Matic et al. 2018; Ridker 
et al. 2009). 
C-reactive protein (CRP) in blood, measured by high sensitivity assays, has been linked 
to increased risk of cardiovascular disease (Ridker et al. 2009; Slijkhuis et al. 2009), although 
other factors such as infectious diseases may also increase CRP. However, Narula et al. showed 
that local factors such as inflammation in individual atherosclerotic plaques are associated with 
a higher risk of rupture and might be better predictors for risk stratifications (Narula et al. 2008; 
Narula et al. 2007). Some of the underlying mechanisms of plaque rupture have been identified 
and include inflammation, protease activity, apoptosis, and prothrombotic factors, for example 
tissue factors (Geovanini et al. 2018). Despite many theories being developed in past years, the 
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precise mechanisms responsible for plaque rupture are unknown and not easily predicted; 
hence the importance of improved diagnostic tools. 
 
2.2.2 Pathogenesis of Atherosclerosis  
Atherogenesis is the process of forming plaques in the intimal layer of arteries. Atherosclerosis 
is a disease in which the inside of an artery narrows due to the buildup of plaque. Today, the 
general concept of atherosclerosis as a chronic inflammatory disease is well established. The 
inflammatory processes in the arteries develop over decades and involve endothelial 
dysfunction and abnormal accumulation of lipids. The lesion progression may be histologically 
classified into different phases (Stary grade I-VI) and different types of plaque—stable and 
unstable or vulnerable—which also facilitate the understanding of disease progression (Stary 
et al. 1995; Stary et al. 1994). 
 
2.2.2.1 Endothelial Function and Dysfunction in Atherosclerosis  
Normal arteries have designated layers. Starting from the lumen, the endothelium is a 
monolayer of endothelial cells (ECs) that lines the inner wall of the vasculature and, together 
with subendothelial connective tissue, compromises the tunica intima. The next layer is built 
up with connective tissue and several layers of smooth muscle cells (SMCs), responsible for 
vascular elasticity, and is called the tunica media. The outermost layer, called tunica externa or 
the adventitia, consists of connective tissue, small blood vessels, lymphatic vessels, nerves, and 
surrounding perivascular fat.  
ECs are key players in acute and chronic inflammatory reactions within the arterial 
wall (Gimbrone et al. 2016). In a healthy state, the endothelium maintains homeostasis by 
controlling vascular tone and vascular permeability. The endothelium has the ability to produce 
substances that affect both vasoconstriction and vasodilation (Furchgott et al. 1980). ECs are 
affected by the tangential force of the flowing blood on the vascular bed, (i.e. the shear stress). 
In laminar flow, the shear stress is high, promoting EC survival, alignment in the direction of 
flow, and upregulation of atheroprotective transcription factors such as Kruppel-like factor 4 
(KLF4) (Zhou et al. 2012) or production of vasodilators and anticoagulant factors. In turbulent 
flow with low shear stress, often seen in inner curvature and bifurcations, plaques are more 
likely to develop due to endothelial cell dysfunction (Chiu et al. 2011; Hsieh et al. 2014). This 
process is associated with impaired production of the vasodilator nitric oxide (NO). The 
decrease in NO will in turn lead to increased vascular permeability and vascular tone. At the 
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sites of low shear stress, gene expression alterations via nuclear factor kappa B (NF-κB) 
pathways activate the endothelium and upregulate adhesion molecules, pro-inflammatory 
chemokines, and cytokines that will attract leucocytes (Nakashima et al. 1998). Adhesion 
molecules are expressed early in atherosclerosis (Cybulsky et al. 2001; Davies et al. 1993; 
O'Brien et al. 1993). The process of transendothelial migration of leucocytes into the intima is 
assisted by the expression of endothelial ligands. The immune cells recognize the ligands by 
their surface antigens. The process starts with leucocyte rolling and binding to E-selectin and 
P-selectin on the endothelium. Firm adhesion of the leucocyte is mediated by the vascular cell-
adhesion molecule 1 (VCAM-1) and intracellular adhesion molecule 1 (ICAM-1). Next, the 
leucocyte transmigrates by crawling—either paracellularly, between endothelial connections, 
or transcellularly—across the EC, into the subendothelial space (Leon et al. 2008; Schnoor 
2015). Adhesion molecules are one of the most studied targets for molecular imaging of 
inflammation in atherosclerosis (Behm et al. 2008; Gargiulo et al. 2016; Kaufmann et al. 2007a; 
Klibanov et al. 2006; Villanueva et al. 1998). 
 
2.2.2.2 Lipid Metabolism 
Lipids are the collective term for fatty acids, triglycerides (TGs), and certain components of 
the membrane such as phospholipids and cholesterol.  
  
Figure 2.1: Examples of the different lipoproteins and their lipid and protein content. Refer to text for 
detailed explanation. Picture reference from Cornell B, 2016. Lipoproteins. Available at: http://ib.bioninja.com.au 
[Accessed 28 January 2019]. 
  
Blood lipids are derived from endogenous biosynthesis and dietary intake lipids. Lipids 
are hydrophobic and therefore carried in association with proteins called apolipoproteins (apo), 
the combination being referred to as lipoproteins. Lipoproteins are hydrophilic structures of 
phospholipid shells and may comprise several apolipoproteins. They carry a “cargo” of 
triglycerides, free cholesterol, and cholesteryl esters. Lipoproteins are classified, based on their 
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size and density, as chylomicrons (CMs): very low, intermediate, and low- or high-density 
lipoproteins (VLDL, IDL, LDL or HDL respectively), Figure 2.1. CMs are produced in the 
intestine from dietary lipids, consist mainly of TGs, and contain apolipoprotein B48, C and E 
(ApoB-48, ApoC, ApoE).  
 
Figure 2.2: Schematic illustration of the major normal lipoprotein metabolic pathways. Blue arrows refer to 
points of action of the respective enzymes in blue. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-
binding cassette transporter G1; ApoA-I, apolipoprotein A-I; ApoA-IV, apolipoprotein A-IV; CE, cholesterol 
ester; CETP, cholesteryl ester transfer protein; FFA, free fatty acid; HTGL, hepatic triglyceride lipase; IDL, 
intermediate-density lipoprotein; LCAT, lecithin–cholesterol acyltransferase; LDL-R, LDL receptor; LPL, 
lipoprotein lipase; LRP, LDL-R–related protein; SR-B1, scavenger receptor B1; TG, triglyceride; VLDL, very 
low-density lipoprotein; VSMC, vascular smooth muscle cells. Reproduced from (Kronenberg 2018), with 
permission from the American Society of Nephrology. 
 
CMs are transported via the lymphatic system to the blood circulation where they 
become remnant CMs after the removal of TGs. This is accomplished by the enzyme 
lipoprotein lipase releasing free fatty acid to the adipose tissue and muscles together with 
glycerol for glucose synthesis in the liver. CM remnants are then transported back to the liver. 
VLDL is largely produced in the liver and contains mainly TGs and apolipoprotein B100 
(ApoB100), but it also acquires ApoC and ApoE. After the release of TGs it becomes IDL. 
LDL is derived from VLDL in the bloodstream and contains mainly cholesterol and ApoB100 
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as its major structural protein. The LDL receptor (LDLR) mediates the uptake of LDL from 
the bloodstream into hepatic cells and the cells of the peripheral tissue. Once LDL is bound to 
LDLR, the complex is endocytosed, free cholesterol is released into the cell, and LDLR 
recycled back to the cell surface. LDL is considered to be pro-atherogenic and is often referred 
to as the “bad cholesterol” in everyday speech since it transports hepatic lipids to the peripheral 
tissue (including atherosclerotic plaques) and is the main carrier of cholesterol in humans. On 
the other hand, HDL—referred to as the “good cholesterol”—is believed to be atheroprotective, 
transporting cholesterol from the peripheral tissue to the liver, and has Apolipoprotein A1 
(ApoA1) as the major structural lipoprotein (Baynes 2018; Feingold 2018).  
The HDL particles may to some extent protect the artery from cholesterol overload by 
facilitating cholesterol efflux from the lipid loaded cells in the vessel wall—a process known 
as reverse cholesterol transport, promoting plaque reduction. Reverse cholesterol transport on 
macrophages is mediated via four efflux pathways. The two passive diffusion pathways are via 
aqueous diffusion and via facilitated diffusion (SR-B1-mediated pathways). The two active 
processes involve members of the ATP-binding cassette (ABC) family of transmembrane 
transporters, namely ATP-binding cassette transporter A1 (ABCA1) and ATP-binding cassette 
transporter G1 (ABCG1) on macrophages. Free excess cholesterol is also transported to ApoA1 
and ApoA1V on HDL particles. The HDL particles can transform into larger particles (HDL3 
and HDL2) by acquisition of additional cholesteryl esters, triglycerides and apolipoproteins. 
Large HDL particles bind to SR-B1 in liver and steroidogenic tissues and release their cargo to 
the cells. HDL can also interact with the cholesteryl ester transfer protein (CETP) that facilitates 
an exchange of cholesteryl esters (CEs) and TGs between LDL particles (Kronenberg 2018; 
Phillips 2014), Figure 2.2. Excess intracellular cholesterol can also be effluxed to ApoE-
containing lipoproteins, produced mainly by hepatocytes and macrophages, for transportation 
to the liver (Getz et al. 2009; Seo et al. 2015). 
Hyperlipidemia is one of the risk factors of CVD and a cornerstone of medical 
treatment is the use of lipid lowering drugs such as HMG-CoA reductase inhibitors, popularly 
known as “statins”, which block cholesterol synthesis in the liver. The lipid-lowering effect 
from statins is not only due to reduced biosynthesis, but also to the concomitant upregulation 
of LDLR in the liver (Ridker et al. 2009; Tang et al. 2009a; Tawakol et al. 2013; Wu et al. 
2007). A new class of lipid-lowering drugs, the proprotein convertase subtilisin/kexin type 9 
(PCSK9)-inhibitors, can be applied to reduce the lysosomal degradation of LDLR via PCSK9, 
further increasing LDL clearance. This drug has been approved for the treatment of patients 
with familiar hypercholesterolemia (Ahn et al. 2015). 
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2.2.2.3 Lipid Dysregulation and Formation of Foam Cells (Stary grade I-II) 
LDL particles from the bloodstream can infiltrate the vessel wall and become modified. The 
initiation of atherosclerosis involves accumulation of lipids in the intimal layer, triggering an 
inflammatory response by secretion of cytokines by leukocytes and upregulation of adhesion 
molecules on ECs. Circulating monocytes in the bloodstream will respond to the expression of 
adhesion molecules on the EC surface and migrate into the intima of the arterial wall, where 
they become macrophages (Libby 2002; Stary et al. 1994). Accumulation of LDL particles in 
the arterial wall leads to modifications, such as oxidation, and the modified particles will be 
taken up by macrophages transitioning them into foam cells (Stary grade I), a hallmark of early 
atherosclerosis. Foam cells are defined as cells with numerous lipid droplets. The uptake of 
modified LDL by macrophages and foam cells can occur via scavenger receptors (SRs) 
(Kunjathoor et al. 2002). Further information about SRs and the role of macrophages is 
described in section 2.3.2.  
An imbalance of cholesterol uptake and efflux can cause the free non-esterified 
cholesterol in plaque to form cholesterol crystals that serve as pro-inflammatory stimuli. When 
the lesion accumulates foam cells and lipid-laden SMCs, it will give rise to fatty streaks (Stary 
grade II) (Chellan et al. 2016; Stary et al. 1994). Oxidized low-density lipoprotein (oxLDL) 
and oxidized phospholipids (oxPL) have been associated with high cardiovascular risk (Byun 
et al. 2017; Tsimikas et al. 2012; van der Valk et al. 2016). During oxidation of LDL, the by-
products of lipid peroxidation generate many pro-inflammatory chemical modifications of both 
the lipid and protein moieties, collectively termed oxidation-specific epitopes (OSEs). 
Examples of OSEs are oxPL and malondialdehyde (MDA) epitopes, both of which are well 
defined chemically and immunologically. They represent danger-associated molecular patterns 
(DAMPs) and induce a pro-inflammatory response (Binder et al. 2016; Miller et al. 2011). 
 
2.2.2.4 Lesion Progression and Plaque Vulnerability  
As lesion development progresses, macrophages, foam cells, and lipid-laden SMCs continue 
to gather and larger deposits of lipids accumulate inside the plaque (Stary grade III). Dense 
accumulation of extracellular lipid promotes lipid core formation and inflammatory cell 
infiltration (Stary grade IV). The pro-inflammatory milieu triggers SMC proliferation and 
migration with an increased extracellular matrix (ECM) and a covering layer of connective 
tissue called the fibrous cap. The lesion may undergo positive remodeling in an attempt to 
resolve inflammation without luminal narrowing. As the lesion increases in size, an increase in 
fibrosis and intimal thickening is observed. The so called fibroatheroma, classified by Virmani 
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et al. (Virmani et al. 2000), consist of the classical lipid core and fibrous cap (Stary grade V). 
At this stage of atheroma, lesions are usually still asymptomatic. 
The naturally phagocytic macrophages will not only endocytose lipids, but also cell 
debris from dying cells undergoing programmed cell death—so-called apoptosis. Apoptotic 
material and cellular debris make up the necrotic core of the lesion. The process whereby 
phagocytic cells remove necrotic or apoptotic cells is called efferocytosis (Moore et al. 2011). 
In the cascade of pro- and anti-inflammatory signaling, non-resolving inflammation will 
eventually trigger a destruction of the intima. As the lesion progresses, with luminal narrowing 
and lesions becoming more advanced, proteolytic degradation of ECM by matrix 
metalloproteases (MMPs) results in thinning of the fibrous cap and gives rise to thin cap 
fibroatheroma, defined as less than 65 µm thickness (Narula et al. 2013; Virmani 2003). Other 
features, such as cholesterol crystals and intraplaque hemorrhage, may also be visible. At this 
stage of the disease, the lesions are more disorganized and symptoms are likely to appear. 
Deposits of calcium ranging from microcalcification to larger calcified nodules and whole 
plaque calcifications may be observed. Calcification is usually a feature of more stable plaques, 
but can cause plaque instability if it occurs in small nodules—a feature associated with 
increased risk of cardiovascular events (Ruiz et al. 2015; Sage et al. 2010). The calcified 
nodules can be imaged by ultrasound, giving rise to a “spotty” appearance (Ehara et al. 2004).  
As the lesion grows, the disease burden increases and some of the areas inside the 
plaque will become hypoxic and trigger the formation of new blood vessels (a process known 
as neovascularization). This process is a target for molecular imaging. At this point, the plaque 
harbors features of high vulnerability with an increased risk of plaque rupture or erosion. The 
rupture of the plaque normally occurs at the edges of the lesion; the so-called shoulder regions, 
with great mechanical stress. In plaque erosion, the endothelial layer is absent, revealing 
thrombogenic material such as tissue factor and collagen and triggering a coagulation cascade, 
with platelet aggregation and thrombosis (Virmani et al. 2002). Thrombus formation (Stary 
grade VI) does not necessarily lead to an acute blockage of the vascular lumen and might, 
instead, partially dissolve. The ruptured plaque will then heal and often cause an increase in 
lesion size (Libby et al. 2005; Sanan et al. 1998; Virmani et al. 2000). However, if the stenosis 
is significant, either because of an obstructive lesion or a thrombosis blocking the blood flow 
in a coronary or carotid artery following rupture or erosion, this could lead to decreased 
perfusion in the heart or brain tissue and result in ischemic myocardial infarction or ischemic 
stroke. 
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2.2.3 Inflammation in Atherosclerosis 
Although this thesis focuses on targeting activated endothelial cells and SRs on macrophages, 
it is important to understand the complex interplay between the cells in the atherosclerotic 
plaque. Inflammatory cells and their mediators are key players in atherosclerosis and involve 
cells from both the adaptive and innate immune systems. The immune cells will react to 
molecular structures, triggering an inflammatory cascade. In atherosclerosis, these altered 
structures include modified LDL (e.g. oxLDL), cholesterol crystals, degraded material, and 
debris from ECM (Geovanini et al. 2018; Libby 2002). A schematic drawing of the 
atherosclerotic plaque components and the inflammatory mediators is shown in Figure 2.3. 
 
Figure 2.3: Illustration of the effector cells in atherosclerosis and the most common molecular imaging 
targets of atherosclerotic plaques (adhesion molecules, macrophages, neovascularization and 
microcalcification). Circulating inflammatory cells are recruited to the plaque by cytokines, chemokines, and the 
expression of adhesion molecules on the endothelial cell surface. In the intima, the monocytes differentiate into 
macrophages and ingest modified LDL (mLDL). Macrophages transform into foam cells with lipid droplet 
accumulation and some cells will undergo apoptosis, eventually leading to the formation of a lipid/necrotic core. 
Vascular smooth muscle cells constitute the media and contribute to fibrous cap formation. Other present cells are: 
T-lymphocytes, dendritic cells, and mast cells. Some of these cells are localized in the adventitia together with B-
lymphocytes (ATLOs).  
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Factors affecting the trafficking of immune cells in the atherosclerotic plaque may be 
divided into pro-inflammatory and anti-inflammatory factors. Such signaling molecules are 
called cytokines or chemokines, a subclass of cytokines. These are produced by cells within 
the plaque. The typical cytokines affecting plaque progression and, hence, regarded as pro-
inflammatory, include interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α), and 
interleukins such as IL-1β and IL-6, while the atheroprotective, anti-inflammatory cytokines 
include transforming growth factor beta (TGF-β), IL-4 and IL-10. Important chemokines in 
atherogenesis, which function to attract monocytes to penetrate the intima, include monocyte 
chemoattractant protein-1 (MCP-1/CCL2). The chemokine that attracts T-cells to plaque is 
regulated on activation, normal T cell expressed, and secreted (RANTES/CCL5). Hence, 
cytokines function to direct extravasation, polarization, and differentiation of cells. 
Chemokines attract and recruit cells to enter the tissue via a process known as chemotaxis 
(Hansson et al. 2006). TGF-β functions to stimulate extracellular collagen maturation, 
stabilizing the plaque and positively regulating the synthesis of collagen by SMCs (Amento et 
al. 1991). IFN-γ, on the other hand, destabilizes the plaque by inhibiting SMC differentiation, 
proliferation, and collagen production and maturation. A link between the cholesterol 
metabolism and innate immunity is the NLRP3 inflammasome, activated by cholesterol 
crystals in foam cells, that leads to the secretion of IL-1β (Duewell et al. 2010). IL-1β stimulates 
the production of IL-6 in SMCs and macrophages (Loppnow et al. 1990), which in turn signal 
the liver to produce CRP (Hansson 2005). Recently, monoclonal antibodies that specifically 
target IL-1β (Canakinumab) have been developed. The clinical trial CANTOS showed that 
explicitly targeting inflammation can reduce clinical cardiovascular events (Ridker et al. 2017). 
 
2.2.3.1 Monocytes and Macrophages in Atherosclerosis 
Origin: Myeloid progenitor cells in the bone marrow give rise to monocytes, macrophages, 
dendritic cells, neutrophils and mast cells, among others. Recent studies on linage tracing of 
cells in atherosclerotic plaques have shown that lesional cells expressing macrophage markers 
can also originate from vessel wall-derived cells, such as transdifferentiated vascular SMCs 
(Bennett et al. 2016), although their properties and fate are still largely undefined. Hence, not 
all macrophages are necessarily myoleoid progenitors derived from circulating monocytes. In 
many organs, adult tissue macrophages originate during embryonic development and not from 
circulating monocytes. They are proliferative cells maintained by self-renewal and are located 
in many different organs of the body, functioning as a first line of defense in response to 
pathogens and microbial infections. Tissue resident macrophages are found in the brain, lungs, 
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liver (Kupffer cells), spleen, adipose tissue, and in the peritoneum (Hashimoto et al. 2013; 
Hoeffel et al. 2015; Yona et al. 2013). Mouse peritoneal macrophages are among the best-
studied macrophage populations in terms of cell biology, development, and inflammatory 
responses (Cassado Ados et al. 2015). 
Recruitment of circulating monocytes: Monocytes circulate in the bloodstream and 
are drawn to migrate into intima upon chemokine secretion and endothelial cell activation. 
Monocytes are a heterogeneous population, giving rise to different polarized macrophages in 
the tissue upon cytokine stimulation and other stimuli. In mice, monocytes may be divided into 
pro-inflammatory Ly6Chi and patrolling Ly6Clow monocytes. In humans the corresponding 
subsets are CD14high/CD16neg (Moore et al. 2011; Woollard et al. 2010). 
Macrophages: Ly6Chi monocytes transmigrate into the subendothelial space and 
differentiate into inflammatory macrophages. These naturally phagocytic cells of the innate 
immune system play a central role in the initiation, progression, and resolution of 
atherosclerosis (Moore et al. 2018). One can view this as a vicious cycle of events leading to a 
chronic inflammatory state.  
Macrophage proliferation: In an initial state, proliferating macrophages act to control 
the disease and ingest retained and modified lipoproteins via phagocytosis, pinocytosis, or 
receptor-mediated pathways such as SRs and toll-like receptors (TLRs) (Tabas et al. 2015). 
Eventually the macrophages will be transformed into foam cells. Cholesterol efflux to HDL 
from the macrophages is facilitated by ABCA1 and SR-B1 to HDL for transportation to the 
liver (Phillips 2014; Webb et al. 1998).  
Macrophage retention: If the amount of lipoproteins and cholesterol engulfed by the 
macrophages exceeds the capacity of reverse cholesterol transport, accumulation will occur 
within the macrophages. Accumulating lipid-laden macrophages in atherosclerotic plaques 
have a diminished migratory capacity, which contributes to failure to resolve inflammation and 
thus leads to advanced and complex plaques. 
Macrophage death and failed resolution: An overload of free cholesterol leads to 
endoplasmatic reticulum stress and pro-inflammatory signaling, causing the macrophage to 
eventually undergo apoptosis or necrosis, with the latter exposing intracellular material. The 
apoptotic/necrotic cells and cellular debris can be cleared by neighboring macrophages. 
However, if there is an imbalance in the dying-cell clearance capacity of the macrophages—
so-called impaired efferocytosis—this will add up to a lipid rich necrotic core that aggravates 
inflammation and gives rise to a persistent immune cell infiltration. Hence, advanced 
atherosclerotic lesions result from the defect resolution of inflammation. Secretion of reactive 
oxygen species (ROS) increases oxidative stress, and secretion of proteases such as MMPs 
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leads to ECM degradation and weakening of the fibrous cap. Macrophages may also secrete 
prothrombotic factors, promoting thrombus formation (Moore et al. 2018; Moore et al. 2011). 
Polarization of macrophages: The polarization of macrophages is based on 
environmental signals such as cytokines, macrophage colony-stimulating factor (M-CSF), and 
interleukins. Macrophages can switch from different polarized states depending on external 
signals. This will cause changes in gene transcription and, hence, the expression of different 
surface molecules. Importantly, macrophages in human atherosclerotic lesions consist of a 
spectrum of intermediate phenotypes. However, traditionally macrophages are divided into the 
classically-activated pro-inflammatory M1 macrophages and the alternatively-activated anti-
inflammatory M2 macrophages. The polarization into M1 macrophages is driven by cytokines 
such as TNF-α and IFN-γ as well as by bacterial lipopolysaccharide (LPS) and, in 
atherosclerosis, also by oxLDL and cholesterol crystals as triggers of cytokine secretion. M1 
polarized macrophages in the plaques are a source of pro-inflammatory cytokines such as IL-
1β, IL-6, IL-12, and TNF-α in addition to a broad range of MMPs. They also express 
chemokine receptor ligands, produce reactive oxygen species (ROS), and activate inducible 
nitric oxide synthase (iNOS), an enzyme catalyzing the production of NO from L-arginine. NO 
is an important modulator of vascular tone and insulin secretion and participates in anti-
bacterial defense via oxidative processes. Taken together, these promote further recruitment of 
leucocytes; hence, M1 macrophages are considered to promote atherosclerotic development. 
M2 polarization is induced by IL-4 and IL-13, and these macrophages are able to 
secrete fibronectin and TGF-β and express mannose receptor (MR). These macrophages are 
considered to have a resolving function that promotes plaque regression (Colin et al. 2014; 
Moore et al. 2013; Moore et al. 2011; Peled et al. 2014). M2 macrophages may be further 
subclassified into M2a, M2b, and M2c (Bobryshev et al. 2016). M1 and M2 macrophages have 
been extensively studied in atherosclerosis and have been histologically localized in the fibrous 
cap, and M1 has also been identified in the shoulder regions of the plaque (Stoger et al. 2012). 
However, M1 and M2 macrophages do not cover the full spectrum of macrophage polarization 
and other subsets of polarized macrophages have been identified in atherosclerotic plaques, as 
reviewed by Bobryshev and Martinez (Bobryshev et al. 2016; Martinez et al. 2014). 
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2.2.3.2 Other Inflammatory Cells in Atherosclerosis 
Different cells from the innate immune system, such as neutrophils, mast cells, and natural 
killer cells, may play important roles at different stages of the disease development, but these 
cells constitute minor populations in the plaque compared to macrophages. Macrophages are 
also regarded as the main effector cell type in the plaque. 
Mast cells: Mast cells are commonly found at sites of plaque rupture and release 
MMPs, which degrade the ECM and promote plaque instability (Kovanen et al. 1995). These 
cells may be found near plaque neovessels and may play a role in neovessel formation and 
intraplaque hemorrhage by increasing leakage from neovessels (Bot et al. 2015). 
Neutrophils: Neutrophils are mainly involved in the early phases of atherosclerosis and 
are one of the first inflammatory cell types to enter the tissue in response to inflammatory 
stimuli. Neutrophils have been associated with plaque progression due to the secretion of 
proteases and ROS adding to the oxidative stress in the lesion (Naruko et al. 2002; Weber et 
al. 2008). 
Dendritic cells: Dendritic cells are antigen-presenting cells that are important for 
adaptive immunity, derived from blood monocytes or lymphoid precursors, and found in 
atherosclerotic lesions, as well as adjacent to lymph nodes and tertiary lymphoid tissues in the 
adventitia. The arterial tertiary lymphoid organs (ALTOs) serve as an interaction site for B 
cells, T cells, and dendritic cells. In atherosclerosis dendritic cells act as mediators between 
innate and adaptive immunity, presenting internalized antigens such as oxLDL on class II 
major histocompatibility complex (MHC) to T cells (Zernecke 2015). 
Lymphocytes: Lymphocytes, derived from common lymphoid progenitor cells, are 
cells of the adaptive immune system including both T- and B-lymphocytes. Activated T cells, 
especially CD4+ T cells (Treg and Th), are a significant population in atherosclerotic plaque. 
CD4+ cells are the main effector cells in the adaptive immune system in atherosclerotic plaque 
(Zhou et al. 1996). Pro-inflammatory Th1 cells can secrete IFN-γ, promoting monocyte 
infiltration and macrophage activation (Buono et al. 2003; Zhou et al. 2006). Th2 cells are less 
frequently found in atherosclerotic plaque and are considered to be of minor importance for 
atherogenesis. Other minor populations of T cells in the atherosclerotic plaque are 
proatherogenic Th17 and antiatherogenic Treg cells, the latter secreting anti-inflammatory 
cytokines such as IL-10 and TGF-β (Gotsman et al. 2008; Ketelhuth et al. 2016). B cells, 
however, are rarely found in atherosclerotic plaques, but can be found in the adventitia below 
the intimal lesion. Circulating antibodies have been detected that target frequently-observed 
antigenic derivatives from atherosclerotic plaques. Many studies have focused on B cell 
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epitopes present in modified LDL. The presence of antibody producing B cells and the potential 
beneficial effect of various antibodies have led to the idea that vaccination against modified 
LDL might be possible. Initial studies have focused on oxLDL or malondialdehyde-modified 
epitopes in LDL, although vaccination with native LDL also shows a significant protective 
effect in animal studies (Hansson et al. 2011; Nilsson et al. 2012; Shevach 2009). 
 
2.2.3.3 Vascular SMCs in Atherosclerosis 
Vascular SMCs (VSMCs) constitute one of the major cell types found in the atherosclerotic 
lesion. In normal arteries, SMCs in the media maintain muscle tone. During atherogenesis these 
cells undergo phenotypic changes and lose their homeostatic function. In early atherogenesis, 
VSMCs are activated by the presence of modified LDL in the intima. Previous studies have 
described these phenotypic changes in VSMCs as a change from a synthetic state—expressing 
classical markers such as smooth muscle alpha actin (Acta2), calponin, and smooth muscle 
myosin heavy chain (Myh11)—to a proliferating and migrating phenotype, downregulating 
genes and hence losing the expression of classical VSMC markers (Alexander et al. 2012). 
More recent studies using lineage tracing of VSMCs have shown that these cells undergo 
phenotypic switching, acquiring a more macrophage-like phenotype inside the plaque. This 
transdifferentiation of vascular SMCs has been recognized in vitro and in animal models; 
however, further validation in human samples is needed. Moreover, the proliferation of 
VSMCs in early atherogenesis seems to have a reparative role in atherosclerosis because of the 
production of ECM and formation of fibrous caps. The role of VSMCs’ migration in human 
atherosclerosis is not fully understood due to a lack of specific markers in this process. 
However, the inflammatory milieu in plaques will also result in lipid-laden VSMCs that further 
increase MMP secretion and cytokine production, eventually forcing the VSMCs to become 
senescent, unable to divide, and undergo cell death, adding to the disease burden (Bennett et 
al. 2016). 
 
2.2.4 Animal Models Utilized in the Imaging of Atherosclerosis 
Animal models for studying atherosclerosis include mice, rabbits, pigs, and non-human 
primates, although the latter two have become less frequently used (Getz et al. 2012). Ideally, 
animal models of atherosclerosis should have similar lipoprotein profiles and lesional 
formation as humans. Lesion development should contain all stages of disease including plaque 
rupture and thrombosis. The Watanabe heritable hyperlipidemic (WHHL) rabbits, which were 
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developed by Dr. Yoshio Watanabe at Kobe University in Japan (Watanabe 1980), have 
contributed to ground-breaking discoveries in understanding the impact of lipoproteins on 
atherosclerosis. These pioneering studies using rabbits established the basis for the modern 
theory of atherosclerosis: the “lipid hypothesis” and the role of lipids as proatherogenic in 
addition to the “inflammatory hypothesis” and the role of inflammatory cells such as 
macrophages and T lymphocytes as the key cellular components for the initiation and 
progression of atherosclerosis (Geovanini et al. 2018; Hansson 2005; Moore et al. 2011). Other 
transgenic and gene knock-out (KO) models have also been used in rabbits. However, since 
the beginning of 1990s when the development of genetically modified KO models in mice took 
off, there has been a reduced trend in using rabbit KO models (Fan et al. 2015).  
Ever since the mouse KO model was introduced, it has been widely utilized in 
atherosclerosis, mainly because of their similarity to the human genome and the convenient 
possibility of genetic manipulations for studying disease mechanisms. Another advantage is 
that the progression of the disease is rather rapid in these animals. In WT mice, the majority of 
the cholesterol is in the form of HDL (~ 85%) whereas for humans the majority is in the form 
of LDL (~ 65-85%). WT mice do not naturally develop atherosclerosis; therefore, they must 
be manipulated to better mimic a human lipoprotein profile and a significant 
hypercholesterolemia is needed to induce atherosclerosis in these models. High-fat and 
cholesterol enriched diets are therefore utilized. The most common mouse models in 
atherosclerosis are ApoE deficient (Apoe-/-) and LDLR deficient (Ldlr-/-) mice (Getz et al. 
2012). The major limitations of atherosclerotic mouse models are differences in the lipoprotein 
metabolism compared to humans and the fact that they do not spontaneously develop plaque 
ruptures, the unstable plaque characteristics seen in human lesions. To better mimic plaque 
vulnerability in mouse models of atherosclerosis and observe plaque rupture, cuffing or ligation 
of the artery has been used (Sasaki et al. 2006). Furthermore, the locations of lesions are not 
identical to the arterial sites of lesions in humans. In mice, lesions are often restricted to the 
upper part of the aorta; the aortic root, and the aortic arch, and the carotid arteries, whereas 
lesion in the abdominal aorta is not as dominant as it is in humans. In the traditional KO mouse 
models coronary lesions are limited or absent (Kapourchali et al. 2014). In combined KO 
models, such as the combination of ApoE and SR-B1 deficiencies, lesions of the coronary 
artery can develop (Braun et al. 2002). Cross breeding of human apoB100 transgenic mice with 
LDL receptor-deficient mice will also aggravate lesion formation (Sanan et al. 1998). Other 
combinations with either Apoe-/- or Ldlr-/- backgrounds have also been utilized (Kapourchali et 
al. 2014). The atherosclerotic mouse model included in this thesis is the Apoe-/- mouse. The 
most common animal models of atherosclerosis are summarized in Table 2.1. 
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Table 2.1: Animal models of atherosclerosis and their characteristics. 
Animal model Characteristics of 
atherosclerosis 
Lesion formation    
(stages and locations) 
Comparison 
to humans 
Reference 
Mice   
Apoe-/- Develops spontaneous 
atherosclerosis, which is 
accelerated by feeding 
with fat- and cholesterol-
enriched diets.  
Elevated levels of 
circulating cholesterol-
rich VLDL particles. 
Stages of lesion formed (I-V). 
Aortic root, aorta (carotid 
artery, older mice). 
Lipoprotein 
profile, site 
and type of 
lesions 
differs. 
(Zhang et 
al. 1992) 
Ldlr-/- Dietary cholesterol 
necessary for developing 
hypercholesterolemia and 
atherosclerosis. 
Associated with elevated 
levels of circulating 
cholesterol-rich LDL and 
VLDL particles. 
Stages of lesion formed (I-IV). 
Aortic root, aorta. 
Lipoprotein 
profile, site 
and type of 
lesions 
differs. 
(Sanan et 
al. 1998) 
Rabbits   
Watanabe 
Heritable 
Hyper-
lipidemic 
Naturally deficient in LDL 
receptors resembling 
human familial 
hypercholesterolemia. 
(High VLDL/LDLs and 
extremely low HDLs). 
Fatty streaks to advanced 
lesions. Starts in the aortic arch 
and thoracic aorta and finally 
develops in the abdominal 
aorta. Also develops coronary 
atherosclerosis and 
spontaneous myocardial 
infarction. 
Lipoprotein 
profile 
similar to 
humans. 
Similar to 
advanced 
lesions in 
humans. 
(Watanabe 
1980) 
Cholesterol 
fed rabbits 
(New Zealand 
white, and 
Japanese 
white) 
Resembling human 
familial 
hypercholesterolemia.  
(High VLDL/LDLs and 
extremely low HDLs). 
Starts in the aortic arch and 
thoracic aorta and finally 
develops in the abdominal 
aorta. Also develop coronary 
lesions. 
Lipoprotein 
profile 
similar to 
humans. 
Lesion site 
differs. 
(Fan et al. 
2015) 
 
2.3 Molecular Imaging Targets of Inflammation in Atherosclerosis 
Many different molecular probes have been developed for this purpose. The target should be 
valid and relevant to the disease process. It should also be expressed to a measureable extent 
compared to the healthy state or possess clearly altered metabolic activity compared to the 
healthy state. Adhesion molecules and macrophages are amongst the most studied targets for 
molecular imaging of inflammation in atherosclerosis. 
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2.3.1 Adhesion Molecules 
Cell adhesion molecules (CAMs) are a subset of cell adhesion proteins located on the cell 
surface. CAMs are involved in binding with other cells, such as the recruitment of leucocytes 
into the subendothelial space, or binding with the ECM. These molecules are transmembrane 
receptors that comprise an extracellular, a transmembrane, and an intracellular domain. There 
are four major superfamilies or groups of CAMs including: the integrin family, the 
immunoglobulin superfamily, selectins, and cadherins. The most widely studied 
immunoglobulin superfamily for molecular imaging targeting includes ICAM-1, VCAM-1, 
and the platelet-endothelial cell adhesion molecule-1 (PE-CAM-1), while the most studied in 
the selectin family are E-selectin (CD62E) and P-selectin (CD62P) (Elangbam et al. 1997). The 
expression of adhesion molecules such as E-selectin, ICAM-1, and VCAM-1 is induced on the 
surface of the activated endothelial cells lining lipid rich atherosclerotic plaques (Cybulsky et 
al. 2001; Davies et al. 1993; O'Brien et al. 1993). Over-expression of ICAM-1 has been 
demonstrated, not only on the endothelial cells, but also on VSMCs and macrophages of human 
atherosclerotic plaques (Poston et al. 1992; Wood et al. 1993). Davies et al. found that VCAM-
1 appears focally on endothelial cells covering fibrous or lipid-rich plaques and in intraplaque 
neovessels (Davies et al. 1993). VCAM-1 binds the very late antigen-4 (VLA 4) on the surface 
of leucocytes. Preclinical studies have shown that blocking or knocking out this receptor 
significantly inhibits leucocyte recruitment (Koni et al. 2001). VCAM-1 does not seem to be 
significantly expressed on the endothelium in non-affected areas and therefore might serve as 
an interesting diagnostic target to specifically detect inflammatory atherosclerotic lesions 
(Nakashima et al. 1998; Park et al. 2013). Probes for molecular imaging of adhesion molecules 
have been developed for contrast enhanced ultrasound (CEUS) (Behm et al. 2008; Bettinger et 
al. 2012; Kaufmann et al. 2007a; Klibanov et al. 2006; Villanueva 2008; Villanueva et al. 
1998), MRI (Li et al. 2014), and nuclear imaging techniques (Broisat et al. 2014; Nahrendorf 
et al. 2009; Nakamura et al. 2013). 
 
2.3.2 Scavenger Receptors 
Scavenger receptors (SRs) are a group of membrane glycoproteins, first identified in 
macrophages and described by Brown and Goldstein in 1979 (Brown et al. 1979; Goldstein et 
al. 1979) and further characterized by Platt, Greaves and Gordon (Greaves et al. 2009; Platt et 
al. 2001; Platt et al. 2002). The SR-A1 receptor was the first to be discovered because of its 
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ability to mediate the formation of foam cells. Subsequently, many other SRs have been 
discovered.  
Scavenger receptors are defined as cell surface receptors able to bind multiple ligands and 
promote the removal of non self or altered self targets. They often function by mechanisms that 
include endocytosis, phagocytosis, adhesion, and signaling that ultimately lead to the 
elimination of degraded or harmful substances (Prabhudas et al. 2014).  
Since their first discovery 40 years ago, a broad number of different ligands have been 
identified including pathogens; lipopolysaccharide, Gram positive and Gram negative bacteria; 
modified proteins such as acetylated LDL (acLDL), malondialdehyde-LDL (MDA-LDL), 
oxLDL, maleylated (Mal) LDL or albumin, and native protein; ApoA-1, ApoE, lipids, and 
polysaccharides; dextran sulphate and fucoidan; as well as nucleic acids (Ben et al. 2015). 
According to their architecture, they are categorized into eight different classes, termed SR-A 
to SR-H, reviewed by Prabhudas et al. (Prabhudas et al. 2014). Additionally, two other classes, 
SR-I and SR-J have been described but not included in the general SR nomenclature (Zani et 
al. 2015). The classes are subdivided further into “types” based on additional variations in their 
sequences due to alternative splicing. In some of the SR classes, multiple names have been 
assigned to the same receptor subtype. This is the case for the SR class A1, SR-A1 (also known 
as macrophage SR1; MSR1, SCARA1, CD204) and the proposed consensus definition of SR 
nomenclature is presented by Dr. Prabhudas et al., a collaboration of 15 researchers from five 
different countries. The most common SRs involved in the uptake of modified LDL particles 
are the ones from Class A, B, and E. These are listed in Table 2.2. 
 
2.3.2.1 The Role of SR-A1 in Atherosclerosis 
SR-A1 is expressed by macrophages and found in macrophage-rich areas of both human and 
mouse atherosclerosis. However, expression in normal VSMC and EC is low (Gough et al. 
1999; Matsumoto et al. 1990; Naito et al. 1992; Nakata et al. 1999). Expression of SR-A1 is 
seen in mature macrophages of the mononuclear phagocyte system (a.k.a. the 
reticuloendothelial system), such as liver sinusoidal endothelial cells (LSECs) and Kupffer 
cells, alveolar macrophages, or splenic and lymph node macrophages (Hughes et al. 1995). The 
role of SR-A1 in CVD and atherosclerosis is still a matter of debate due to contradictory in vivo 
results. Between 1997 and 2005, many studies conducted in SR-A1 deficient (SR-A1-/-) mice 
with either Apoe-/-or Ldlr-/- backgrounds, showed decreased lesion size upon deletion of the 
gene. Hence, these studies indicated a pro-atherogenic role for SR-A1 (Ben et al. 2015; 
Kunjathoor et al. 2002; Sugano et al. 2001; Suzuki et al. 1997; Zhao et al. 2005). 
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Table 2.2: Scavenger receptor nomenclature and LDL uptake. 
New 
nomenclature 
Currently 
known as 
Encoded by (gene) Modified LDL uptake 
Class A   
SR-A1  SR-A1, 
SCARA1 
MSR1 gene AcLDL, oxLDL, Mal-LDL 
SR-A1.1  SR-AII A splice variant of MSR1 gene AcLDL, oxLDL, Mal-LDL 
SR-A1.2  SR-AIII A splice variant of MSR1 gene  
SR-A6 SCARA2 MARCO  AcLDL 
Class B   
SR-B1 SR-BI SCARB1 AcLDL, oxLDL, native 
LDL, native HDL 
SR-B1.1 SR-BII A splice variant of SCARB1 gene  
SR-B2 SCARB3 CD36 AcLDL, oxLDL 
Class E   
SR-E1 LOX1 ORL1 oxLDL 
Table data from references: (Greaves et al. 2009; Prabhudas et al. 2014) 
 
 Observations that challenge this conclusion (Ben et al. 2015; Kuchibhotla et al. 2008; Moore 
et al. 2005) did not show any significant alteration in plaque size by SR-A1 compared to CD36 
deficiency or when examined in double KO mice models, although some results showed a 
reduction in lesion necrosis, inflammation, and macrophage apoptosis (Manning-Tobin et al. 
2009). Differences in the in vivo observations of the role of SR-A1 in atherosclerosis may be 
due to differences, such as age and diet, in atherosclerotic mouse models. However more recent 
findings have shown that SR-A1 may function via anti-inflammatory responses by, for 
example, promoting an M2 macrophage phenotype in adipose tissue in mice (Zhu et al. 2014). 
Furthermore, Robbins et al. (2013) showed that the accumulating macrophage foam cells in 
the established atherosclerotic lesions primarily originated from a SR-A1-mediated 
proliferative response (Robbins et al. 2013). Previously, it was believed that macrophages did 
not proliferate in the atherosclerotic lesion and that the only sources of new macrophages 
originated from migrating blood monocytes. However, Robbins et al. showed that lesional 
macrophages do proliferate and SR-A1 may therefore contribute to atherogenesis, primarily by 
mediating macrophage proliferation. A large number of macrophages in atherosclerotic lesions 
is an indicator of unstable and rupture-prone phenotypes (Jaffer et al. 2006; Narula et al. 2008; 
Virmani et al. 2002). Nevertheless, SR-A1 is an interesting target for detecting macrophage-
rich inflammatory atherosclerotic plaques with molecular imaging. Promising findings within 
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the field of probe development for molecular imaging was demonstrated in vitro by Lipinski et 
al. (Lipinski et al. 2006) utilizing gadolinium-containing immunomicelle probes for possible 
MRI application as well as in vivo by utilizing SR-A1–targeted iron oxide nanoparticles for 
MRI detection of atherosclerotic lesions (Amirbekian et al. 2007; Segers et al. 2013). 
 
2.3.3 Other Markers 
Other potential molecular targets for molecular imaging are markers of apoptosis, 
angiogenesis, or atherothrombosis. The most extensively studied marker for angiogenesis is 
the αvβ3 integrin, a cell surface glycoprotein receptor expressed by macrophages, medial and 
some intimal SMCs, and endothelial cells. Expression of αvβ3 is found in the shoulder region 
of advanced plaques and in the necrotic core of human atherosclerotic lesions (Antonov et al. 
2004; Byzova et al. 1998; Gargiulo et al. 2016). Thrombotic markers such as glycoprotein (GP) 
IIb/IIIa complex is expressed on the surface of activated platelets. The GP IIb/IIIa receptor is 
a potential marker for the imaging of aggregated platelets in atherosclerotic plaques. Peptides 
containing the Arg-Gly-Asp (RGD) sequence are highly adhesive for GP IIb/IIIa, and the cyclic 
(c) RGD has 30-fold greater affinity for the GP IIb/IIIa complex than the linear form. cRGD is 
also recognized by the αvβ3 integrin receptor (Gargiulo et al. 2016; Schottelius et al. 2009). 
Therefore cRGD has been utilized for targeting purposes by coupling to microbubbles (MBs) 
(Guo et al. 2015; Metzger et al. 2015) in addition to contrast agents used for MRI (Burtea et al. 
2008) and radioisotopes in nuclear imaging (Burtea et al. 2008). 
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2.4 Imaging of Atherosclerosis 
Before elaborating on the imaging of atherosclerosis, some important terminology needs to be 
defined, Table 2.3. 
 
Table 2.3: Imaging terminology.  
Table data from reference (Chen et al. 2011; Chen et al. 2010; Chen et al. 2017; Gropler et al. 2007). DFO = 
deferoxamine, NOTA = triazacyclononane triacetic acid, DOTA = tetraazacyclododecane tetraacetic acid. 
 
Nomenclature Definition 
Molecular imaging In vivo visualization, characterization, and measurement of 
biological processes at the molecular and cellular levels. 
Molecular imaging probes Agents used to visualize, characterize, and quantify biological 
processes in living systems. It can be referred to by many other 
terms, such as ligand, tracer and contrast agent. 
Contrast agents (CAs) Substances used to increase the contrast of structures or fluids 
within the body in medical imaging. CAs absorb or alter external 
electromagnetism or US and are different from 
radiopharmaceuticals, which emit radiation themselves. 
Superparamagnetic  
iron oxide nanoparticles (SPIONs) 
SPIONs are synthesized from iron oxide with ferromagnetic 
properties. The two main forms are magnetite (Fe3O4) and its 
oxidized form maghemite (γ-Fe2O3). When the ferromagnetic 
particles' size is decreased, they obtain superparamagnetic 
properties. Diameter range of nanoparticles between 10 and 100 
nm can be used in medical imaging: standard SPIO (SSPIO), 50-
150 nm; and ultra-small SPION (USPIO) <50 nm). 
Radionuclide (Synonym: 
Radioisotope) 
An atom with excess nuclear energy making it unstable. This 
energy can be emitted in different ways by a process known as 
radioactive decay of an atomic nucleus. 
Radioactive decay Radionuclides can decay, giving rise to different types of 
radiation: alpha, beta, or gamma radiation (or “rays”). One 
radionuclide can decay giving rise to only one or several types of 
radiation. Out of the three types of radiation, gamma rays are the 
most penetrating form of radiation. 
Radiotracer (Synonym: Radioligand) A molecular probe labeled with a radionuclide.  
Metal chelators  Molecules with inherent functionality to capture and bind specific 
metal ions such as DFO, NOTA, or DOTA. 
Spatial resolution Spatial resolution determines how sharp the image will be and is 
defined by the voxel size or the size or number of pixels in one 
image. 
In radiology: the ability of the imaging modality to resolve or 
differentiate between two objects in space. 
In fluorescence microscopy: the minimum separation between 
two points that results in a certain level of contrast between them. 
Temporal resolution Refers to the precision of a measurement with respect to time. 
Voxel  A three dimensional pixel. 
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2.4.1 Angiography 
Conventional angiography was considered to be the standard method for evaluating carotid 
stenosis. Moreover, the trials published in the 1990s (North American Symptomatic Carotid 
Endarterectomy Trial [NASCET], the European Carotid Surgery Trial [ECST], and the 
Asymptomatic Carotid Atherosclerosis Study [ACAS]) were based on this method. However, 
since the introduction and development of Doppler ultrasound, CT angiography (CTA), and 
MR angiography (MRA), conventional angiography has become less popular for carotid 
stenosis diagnostic purposes, essentially being reserved for endovascular treatment (Benjamin 
et al. 2018; Brinjikji et al. 2016; Saba et al. 2010). 
For diagnosis of coronary artery disease, invasive angiography is still considered to be 
the gold standard technique. This technique is based on the radio-opacity of intra-arterially 
injected iodinated contrast agents visualized by x-ray. A pre-shaped catheter is introduced 
percutaneously via the peripheral arteries in the groin (femoral artery) or in the wrist (radial 
artery) to intubate the coronary ostia and inject the contrast agent under x-ray fluoroscopy. The 
advantages of angiography are high diagnostic accuracy afforded by superior spatial (0.1–0.2 
mm) and temporal (10 ms) resolution, which is unmatched by noninvasive techniques (Tarkin 
et al. 2016). Therefore, invasive angiography remains the best anatomic reference test to 
determine the severity of coronary luminal obstruction and guide clinical management, 
particularly for revascularization decisions. However, its limitation is the overall low 
diagnostic yield, restricted to luminal imaging of the degree of vessel stenosis but providing no 
information about vessel components or the functional effects of the stenosis (Patel et al. 2010). 
Angiography is primarily applied in high-risk symptomatic patients and often accompanied by 
opening of the coronary vessel by percutaneous coronary intervention (PCI). Modern clinical 
intravascular coronary imaging techniques include optical coherent tomography and 
intravascular ultrasound (IVUS). IVUS utilizes an intravascular ultrasound catheter and 
provides more details than conventional angiography or ultrasound alone. Grayscale IVUS has 
a limited ability to differentiate individual plaque components but, if combined with virtual 
histology (VH)-IVUS, enables detection of the necrotic core, dense calcium, fibrous, and 
fibrofatty plaque with reasonable accuracy (Nair et al. 2007). Reliable and reproducible 
detection of the thin fibrous cap is limited, with insufficient spatial resolution and artifacts due 
to a low signal-to-noise ratio (SNR). Optical coherent tomography utilizes near-infrared light 
with high spatial resolution, providing accurate measurement of fibrous cap thickness with 
strong correlation to histology (Kume et al. 2006). However, tissue penetration is limited to 3 
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mm, making it hard to image the whole plaque (Gargiulo et al.; Tarkin et al. 2016). Some of 
the noninvasive imaging modalities are listed in Table 2.4. 
2.4.2 Ultrasound 
An ultrasound transducer contains piezoelectric crystals, which both transmit and receive the 
ultrasound signal or sound wave. Various transducers with different frequencies and shapes are 
suitable for specific parts of the body depending on the body surface and depth of penetration 
needed to visualize the organ or structures. Some sound waves will be absorbed by the tissue 
or reflected in other directions and scattered. The reduction in amplitude of the ultrasound beam 
as a function of distance through the tissue is called attenuation, which will affect the resulting 
image. The transducer receives the echoes and sends them to a computer, which uses them to 
create an image or sonogram. Ultrasound B-mode (2D) imaging is well-established as a method 
for visualizing atherosclerosis of the larger arteries, such as carotids, yielding anatomical 
information on plaques that obstruct the lumen of the blood vessel. B-mode ultrasound images 
are also used to assess the echogenicity of plaques, which is proportional to the density of the 
tissue and its capacity to reflect ultrasound (Gropler et al. 2007). Calcifications are strongly 
reflective and may create a shadow. Plaque echolucency, indicating softer, more lipid rich 
tissue, is a marker of plaque vulnerability (Huibers et al. 2016). This feature is seen in up to 
50% of recently symptomatic plaques compared with less than 5% of asymptomatic plaques 
(Huibers et al. 2016). A study by Ballotta et al. (2014) showed that the risk of stroke among 
patients with echolucent plaques is up to 13% regardless of the degree of stenosis, which is a 
higher risk compared to the risk of stroke in patients with high grade stenosis (Ballotta et al. 
2014). 
Thus, measuring the echogenicity of plaques can provide information on whether a 
plaque is “hard” (i.e. fibrotic and calcified [appearing bright and echodense]), or contains a 
darker “soft” core and is assumed to have a high lipid content and little fibrosis (appearing 
echolucent, i.e. black). Since soft plaques are dark, they may be difficult to delineate or even 
to discover in the B-mode image if they have a similar reflectivity as blood. An important use 
of B-mode with color, Doppler (so called Duplex scanning) is used to visualize the blood 
stream and thereby reveal or exclude soft plaque. The composition of plaques, which is likely 
to influence their vulnerability, can be visually interpreted by, for example, applying the Gray-
Weale score (Ballotta et al. 2014). Vulnerability may also be related to the overall echogenicity 
and measured as grayscale median (GSM). Duplex ultrasound (2D-Doppler) allows 
measurement of blood flow velocity and hemodynamic properties for estimation of the severity 
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of carotid stenosis: an accessible imaging technique commonly used in patients with recent 
strokes or as a part of risk assessment scanning (Alonso et al. 2015; Brinjikji et al. 2016). 
2.4.3 Magnetic Resonance Imaging 
MRI is a noninvasive imaging modality based on the magnetic properties of hydrogen atoms. 
The spin vector of the hydrogen atom in a sample is randomly oriented until it is placed in an 
external magnetic field. To give a simplified description, an MR scanner consists of a large 
electromagnet with a static magnetic field in which the patient lies. The resulting magnetization 
of all protons inside the body aligns with the magnetic field. To generate images, spatially 
varying magnetic fields, (i.e. magnetic field gradients) are used to make the resonance occur at 
different frequencies. Very powerful magnets of 1.5 Tesla or more are needed for good 
sensitivity. The corresponding frequencies for hydrogen nuclei are in the range of radio-waves; 
that is, 63 MHz at 1.5 Tesla. A radio wave antenna (coil) is used to send out signals to the body 
and to receive signals back. These signals are then computed into images, Figure 2.5. During 
the image acquisition process, a radiofrequency (RF) excitation pulse is applied to excite the 
spins. After the given pulse, the spins will in time return to the orientations of the magnetic 
field, and the relaxation time can be calculated. By varying the timing of the RF-pulses, using 
more complex sequences of RF-pulses, and switching gradients, the contrast between different 
tissue types can be optimized. However, the lengthy acquisition time of MRI limits the 
temporal and spatial resolution (Gropler et al. 2007).  
 
2.4.3.1 MRI in Atherosclerosis 
The periodic motion of the heart, the pulsatile blood flow, and the motion of the lungs should 
be considered when imaging the heart and nearby vessels. By synchronizing the acquisition of 
the data with the heartbeat, images from different phases of the cardiac cycle can be acquired. 
Electrocardiography (ECG)-triggering can adjust for cardiac movement to provide anatomical 
imaging of vessels in or near the heart. Magnetic resonance angiography (MRA) refers to the 
visualization of flow within vessels and can be performed with or without contrast 
enhancement. In vascular imaging with MRI, both the luminal information and imaging of the 
vessel wall is possible. MRA without intravenous administration of contrast utilizes the 
phenomenon of the flow-related enhancement of spins entering into the image slice, and these 
spins give rise to a stronger signal (brighter appearance) than the surrounding stationary spins 
in the tissue. There are a wide variety of pulse sequences available for plaque characterization 
with MRI and ultimately they result in different image appearances. Examples of such are fast 
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spin echo (FSE) and gradient echo. It is also possible to obtain black blood images, acquired 
using so-called spin-echo, which results in images with high contrast between the dark lumen 
and the vessel wall. MRI is the most well-established imaging modality for plaque 
characterization. It can be used with high reliability to detect intraplaque hemorrhage, lipid 
rich-necrotic cores (LRNC), and thin fibrous caps (Brinjikji et al. 2016; Koppal et al. 2017; 
Tarkin et al. 2016). However, visualization of the carotid arteries is more feasible with MRI 
than of the coronary arteries due to rapid movement of the heart and low temporal resolution. 
MRI can also be combined with other techniques such as PET, which can identify inflamed 
tissue as well as the metabolic state and myocardial ischemia (Tarkin et al. 2016). 
 
2.4.4 Computed Tomography Angiography 
CTA is preferred over MRI for anatomical coronary imaging, primarily because motion 
artifacts arise during the prolonged acquisition time with MRI, resulting in inferior temporal 
resolution. Imaging artifacts with CT may arise from calcification in the coronaries with CT, 
possibly causing difficulty in determining the vascular lumen dimension. CTA can also be 
applied for anatomical carotid imaging and has proved useful for detection of macro 
calcification. CTA is based on rotating an x-ray source and detector in addition to iodinated 
contrast agents for the visualization of vessels. Data from several projections is reconstructed 
into images of multiple planes. CT, preferably without contrast, can be used to differentiate 
soft and calcified lesions to assess the calcium burden in the vessel (calcium score) in selected 
patients with a low to moderate probability of CVD. Determination of the calcium score is 
useful as a negative predictive value, since absence of calcium in the coronary arteries indicates 
a low risk of cardiovascular events (Miller et al. 2008; Shaw et al. 2012; Tarkin et al. 2016).  
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Table 2.4: Noninvasive imaging modalities. 
Noninvasive 
imaging 
modalities 
Spatial 
resolution 
(mm) 
Detection 
limit  
(probe)  
Contrast agent 
or tracer 
Advantages Limitations 
Ultrasound Depends on 
axial and 
lateral 
resolution 
(transducer 
frequency)  
0.3 - 0.1  
(3 - 10 MHz) 
0.03  
(30 MHz ) 
0.04 - 0.1  
(SA-US)  
0.15 - 1  
(C-US) 
Not well 
characterized 
yet 
Microbubbles Real-time 
Low cost 
High temporal 
resolution (s) 
Portable 
No ionizing 
radiation 
Operator-
dependent 
Poor SNR 
 
Magnetic 
resonance 
0.01- 0.1  
(SA-MRI) 
0.5 -1.5   
(C-MRI) 
10
-3
- 10
-5
  
mM to μM 
Gd-based 
contrast agents 
  
Nanoparticles; 
USPIO, SPIO 
High spatial 
resolution and soft 
tissue contrast 
Functional 
parameters 
No ionizing 
radiation 
High SNR 
Toxic effect of 
SPIONs or Gd  
High cost 
Long scans, and 
data post-
processing time 
X-ray 
computed 
tomography 
0.02 - 0.3 
(μCT) 
0.5 - 2  
(C-CT) 
10
-2
- 10
-3
 
(potentially  
10
-9
- 10
-10
  
with NP)
 
mM to nM 
Iodinated 
molecules 
(particles) 
 
Gold nanorods 
Fast acquisition 
time 
High temporal 
resolution (s - min) 
Provides molecular 
and structural 
information 
Ionizing radiation  
Low soft tissue 
contrast  
Medium cost 
Nuclear 
imaging 
1 - 2 
(μPET) 
3 - 5 
(C-PET) 
 
0.5-2  
(μSPECT)  
7-15  
(C-SPECT) 
PET: 
10
-11
- 10
-12
 
pM 
 
SPECT:  
10
-10
- 10
-11
 
nM to pM 
 
Positron or 
gamma ray 
emitting 
radionuclides 
Molecular and 
functional 
parameters 
High sensitivity 
Ionizing radiation  
Poor spatial 
resolution (mm) 
High-medium 
cost 
Photo-
acoustic 
imaging 
< 0.1  < 10
-12
 
pM 
NIR 
Fluorophores 
High sensitivity 
No ionizing 
radiation 
High depth of 
penetration (<5cm) 
Low cost 
Data post-
processing and 
acquisition 
procedures are 
still being 
optimized 
Table reference from (Brinjikji et al. 2016; Chen et al. 2011; Gargiulo et al. 2016; Tarkin et al. 2016). SA = 
small-animal, C = clinical, Gd = Gadolinium, SPIO = Superparamagnetic Iron Oxide, USPIO = ultrasmall SPIO, 
SPIONs = SPIO nanoparticles, SNR = signal-to-noise ratio. 
  Review of Literature 
_________________________________________________________________________________________________________________ 
 
 37 
2.5 Molecular Imaging of Atherosclerosis  
Evidently we cannot rely on the level of stenosis for assessment of plaque vulnerability, since 
plaque vulnerability may be present without a significant degree of luminal stenosis. Features 
of plaque vulnerability include inflammation manifested, for example, as macrophage 
infiltration, a thin fibrous cap, a large necrotic core, hemorrhage, microcalcification, or 
neovascularization (Alonso et al. 2015; Hansson et al. 2015; Naghavi et al. 2003). Some of 
these features can be imaged with molecular imaging and targeted probes. These molecular 
imaging techniques include contrast-enhanced ultrasound (CEUS), MRI, CT, positron 
emission tomography (PET), single-photon emission computed tomography (SPECT), 
fluorescent molecular tomography (FMT), and photoacoustic imaging (PAI) (Brinjikji et al. 
2016; Tarkin et al. 2014). These imaging modalities provide information beyond plaque 
structure, Figure 2.4. 
 
  
Figure 2.4: Both hybrid systems and single modal imaging modalities are available for small-animal molecular 
imaging, and some are illustrated here, as well as SPECT/CT for human use. 
  
 
9.4 T MRI 
MicroPET 
SPECT/CT 
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PET/MRI  
Molecular imaging in small animals 
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2.5.1 Contrast Enhanced US  
Ultrasound characterization of atherosclerotic plaques may be improved by using intravenously 
administrated contrast agents: so-called CEUS. Typically, these contrast agents consist of gas 
filled MBs of lipid or biocompatible polymers such as polyvinyl alcohol. The sizes range from 
1 to 5 μm in diameter. The MBs are used for characterizing the plaque surface and can be used 
to detect surface irregularities due to plaque erosion. The MBs do not diffuse into the 
surrounding tissue and are used for intravascular assessment of vessel lumen and 
neovascularity within the atherosclerotic carotid plaque (Bettinger et al. 2012; Kaufmann 2009; 
Klibanov 2013; Paradossi 2010). 
When acoustic waves encounter MBs, the MBs are compressed by positive pressure 
and expanded by negative pressure. As a result, an asymmetric oscillation of MBs occurs, 
called non-linear oscillation, producing asymmetric echoes. These echoes are different from 
the tissue, producing mainly linear reflected ultrasound, but also second harmonic oscillations 
to a certain extent, which is important for so called tissue harmonic imaging and has 
revolutionized image quality with ultrasound scanning (Caidahl et al. 1998). The asymmetric 
echo harmonics are utilized to differentiate the ultrasound signal originating from the contrast 
agent from that originating from the tissue. The CEUS technique cancels the linear ultrasound 
from tissues and utilizes the non-linear ones from the MBs to highlight contrast in the images. 
When combined with B-mode ultrasonography, CEUS provides further details of plaque 
characterization. More than 90% of echolucent plaques demonstrate contrast enhancement 
(Clevert et al. 2011; Huang et al. 2008). CEUS is prone to an artifact known as pseudo-
enhancement, leading to over-interpretation of vessel wall enhancement. Retention of MBs on 
the plaque surface has been shown to correlate with plaque disruption and inflammation since 
macrophages are known to phagocytose this contrast agent (Lindner et al. 2000). MBs can be 
conjugated further, directly or by an avidin/streptavidin biotinylation method, with targeting 
ligands such as antibodies or peptides, rendering them more specific for the targeting of specific 
biomarkers on the endothelium or activated platelets (Bettinger et al. 2012; Green 1963; 
Klibanov et al. 2006; Palmowski et al. 2008). 
 
2.5.2 Contrast Enhanced MRI 
MR angiography with contrast enhancement utilizes intravenously administrated contrast 
agents, of which gadolinium is the most commonly used. Molecular imaging with MRI is 
performed with two major types of contrast agents: 1) paramagnetic gadolinium-based (signal 
  Review of Literature 
_________________________________________________________________________________________________________________ 
 
 39 
enhancement) or contrast agent with superparamagnetic properties; 2) iron oxide-based 
nanoparticles (signal reduction), such as superparamagnetic iron oxide nanoparticles (SPIONs) 
or ultra-small superparamagnetic nanoparticles of iron oxide (USPIO) for visualization of 
plaque characteristics. Gadolinium-labeled RGD probes for MRI have been used for targeting 
of angiogenesis and have been shown to correlate with evidence of plaque angiogenesis 
(Hatsukami et al. 2000). The surface of the SPIONs are often coated with biocompatible 
molecules such as polymers: poly (vinyl alcohol) (PVA), polyethylene glycol (PEG), dextran, 
dendrimers, or proteins such as albumin (Chiellini et al. 2003; Mahmoudi et al. 2011; Singh et 
al. 2010) to improve biocompatibility and biodistribution, which also allows for targeted 
modifications. USPIO have been used for the visualization of inflammation (Tang et al. 2006; 
Tang et al. 2009b). However, for targeting angiogenesis and inflammation, using a nuclear 
medicine technique would provide greater sensitivity than MR imaging does. 
 
2.5.3 Nuclear Imaging  
2.5.3.1 SPECT 
SPECT is a sensitive noninvasive imaging method based on gamma-ray emitting 
radionuclides, such as 99mTc, 111In, or 123I, which are intravenously injected into the patient. 
There is also a possibility for further modification with ligand coupling for specific targeting 
of different tissues inside the body. A SPECT system is based on a gamma camera: a device 
designed to externally image radionuclide distribution in an object. Such a system consists of 
one or more detectors that can be rotated around the object. Although the images recorded are 
two-dimensional (2D), when a number of images (projections) are acquired by rotating the 
detector around the object, a set of slices representing the three-dimensional (3D) volume can 
be reconstructed. However, information is degraded due the attenuation (absorption) of gamma 
rays in the object. When images are co-registered with those from a conventional CT scanner, 
a correction can be made for the attenuation and the radionuclide distribution can also be better 
coupled to anatomical structures. The spatial resolution of clinical SPECT is around 10-16 mm 
and is hence less ideal for the imaging of small structures. SPECT is applied in myocardial 
perfusion and brain imaging, but can also be used in tumor imaging, infection (leukocyte) 
imaging, thyroid imaging, or bone scintigraphy where a 3D-representation can be helpful 
(Gargiulo et al. 2016; Gropler et al. 2007; Tarkin et al. 2014). Several SPECT tracers have also 
been evaluated for inflammation imaging (Yang et al. 2018), for example, 99mTc-cAb-VCAM-
1 (Broisat et al. 2014), and some are listed in Table 2.6. 
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2.5.3.2 PET  
PET is a very sensitive method, often combined with CT and, more recently, with MRI for 
anatomical imaging. Compared to clinical SPECT, the spatial resolution is superior in clinical 
PET (3-5 mm) and therefore also better for imaging of atherosclerotic plaques. PET, similarly 
to SPECT, uses radionuclides, but instead of gamma-ray emitting radionuclides, the PET 
technology is based on positron (β+) emitting radionuclides. A positron is defined as the 
antiparticle or antimatter counterpart to an electron, and has a positive electric charge (+1) and 
the same mass as an electron.  
A brief mention of PET technology and technical challenges: During radioactive decay 
of the radionuclide, a positron is emitted and moves through the tissue until it encounters an 
electron. The distance is referred to as positron range and varies with positron energy. The 
encounter of an electron with its antiparticle, the positron, leads to annihilation, in which they 
vanish, with the formation of two antiparallel 511 kiloelectron volt (keV) gamma rays 
(photons), equaling the rest energy. These photons travel through the tissue before they reach 
the PET detector. The PET camera, consisting of a ring-like detector system, is able to detect 
these photons on opposite sides, Figure 2.5. The data is transformed into 3D images via 
computational reconstruction algorithms. The absorption and scatter (deflected energy) caused 
by the photon-tissue interaction is defined as the attenuation. Attenuation corrections in PET 
can improve image quality and provide more accurate quantifications of PET data (Conti et al. 
2016; Gropler et al. 2007). 
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Figure 2.5: Schematic representation of the PET and MRI procedures. (A) Schematic showing the basic 
principle of PET imaging, adapted with permission, from the work of Dr. Mike Jackson, Small Animal and 
Materials Imaging Core Facility, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of 
Manitoba. The principle is explained in detail in the text (B) Schematic drawing of an MRI scanner with its main 
components highlighted. 
 
Radionuclides differ in half-life and positron range. The energy of the proton will 
determine the range. The positron range will in turn affect the overall spatial resolution. Typical 
short-range (<1 mm) positron emitters include 11C, 18F, 64Cu, and 89Zr, and long-range (>1 mm) 
positron emitters include 15O, 68Ga, and 82Rb. Furthermore, these radionuclides can be divided 
into pure positron emitters and prompt gamma positron emitters. Gamma radiation emitted in 
decay cascades with the positron emission producing spurious coincidences, which blur the 
PET image and produce quantification errors, as in 82Rb applications. Common radioisotopes 
for PET and SPECT are listed in Table 2.5. When choosing which radionuclide to use one 
should consider the half-life of the radioisotope. In general, short-range positron emitters are 
better suited for the imaging of small structures, since they travel a shorter distance in tissue 
before encountering an electron. The PET radioisotopes with long positron range imply a 
blurring of the radioisotope source distribution and a consequent loss of spatial resolution 
(Conti et al. 2016). In addition, some radioisotopes have an alternative high-energy β− decay 
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that could be used for radiotherapy. The radionuclide can be coupled to a “probe” or “ligand” 
of choice and the combination is called a radiotracer or radioligand. Radioisotopes with a short 
half-life are convenient for compounds that reach their target very quickly, like 15O in brain 
studies or 18F-fluorodeoxyglucose (18F-FGD) used in several applications in oncology (Yang 
et al. 2018), while long lived isotopes are better suited when the target is reached more slowly: 
for example, in immuno-PET, radioisotopes such as 89Zr-labeled (Dilworth et al. 2018; Fischer 
et al. 2013; Zhang et al. 2011) or 64Cu ones can be labeled with monoclonal antibodies for 
imaging (Jauw et al. 2016; van Dongen et al. 2007). 
 
Table 2.5: Examples of PET and SPECT radioisotopes and their properties. 
Radioisotope Half-life  
(t1/2) 
Decay mode 
(Branching β+ 
in %) 
Emitted 
positron 
energy  
E
max 
(MeV) 
Emitted 
positron 
energy  
E
mean
 (MeV) 
Decay product 
PET (pure positron emission) 
15O 2 min β+ (99.9) 1.732 0.735 15N 
11C 20.4 min β+ (99.8) 0.960 0.386 11B 
18
F * 110 min β+ (96.9) 0.634 0.250 18O 
64Cu 12.7 h β+ (17.5) 0.653 0.278 64Ni 
89
Zr * 78.4 h β+ (22.7) 0.902 0.396 89mY 
PET (prompt gamma positron emission) 
82
Rb
 1.3 min β+ (81.8)  
(γ 15.1) 
3.379 (E = 
0.777 MeV) 
1.535 82Kr 
68Ga 67.8 min β+ (87.7)  
(γ 3.2) 
1.899 
(E = 1.077 
MeV) 
0.836 68Zn 
SPECT 
99m
Tc * 6 h γ E = 0.142 
99
Tc 
123
I 13.2 h γ E = 0.159 
123m
Te 
111
In 67.2 h γ E = 0.245 
111
Cd 
Table references (Conti et al. 2016; Gropler et al. 2007). * Indicates the radioisotopes utilized in this thesis.  
 
2.5.4 PET Imaging of Inflammation in Atherosclerosis 
To date there is probably no better non-invasive imaging technique to identify molecular 
processes in the development of atherogenesis than PET. The use of PET tracers for imaging 
of atherosclerosis has become an important area of interest. There are many possible targets for 
the imaging of atherosclerosis and one of the most studied features of plaque vulnerability is 
inflammation, since it is related to a high risk of plaque rupture (Alonso et al. 2015; Hansson 
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et al. 2015; Tarkin et al. 2014; Wu et al. 2013). The most frequently utilized PET tracer, also 
outside the scope of atherosclerotic disease, is 18F-FDG (Hyafil et al. 2018). FDG is a glucose 
analogue taken up in cells primarily via glucose transporters and further phosphorylated by 
hexokinase to FDG-6-phosphate. Unlike glucose, which is phosphorylated to glucose-6-
phosphate, FDG-6-phosphate cannot be further metabolized and is therefore trapped in the 
cells. Therefore, uptake of 18F-FDG is directly associated with glucose metabolism. 
Macrophages and myeloid cells have a high glucose metabolism. Studies have shown that 
polarization of macrophages to M1 phenotype increases 18F-FDG uptake and consumption 
compared to M2 macrophages (Rodriguez-Prados et al. 2010; Tavakoli et al. 2013). 
Interestingly, macrophages seem to have an immunometabolic function in maintaining 
hemostasis in metabolic tissue, but also as a key driver of disease developments such as insulin 
resistance, which leads to diabetes type 2 (Mauer et al. 2010). The pro-inflammatory phenotype 
of macrophages relies on anaerobic glycolysis, which refers to the breakdown of glucose to 
puruvate and conversion to lactate and seems to promote insulin resistance, while the anti-
inflammatory phenotype relies on aerobic metabolism and promotes insulin sensitivity. In 
obesity, the visceral adipose tissue accumulates macrophages of pro-inflammatory phenotype, 
increasing cytokine production and the inflammatory response (Verdeguer et al. 2017), which 
might cause off-target accumulation of 18F-FDG in obese patients.  
Despite the above-mentioned limitation, 18F-FDG has been considered a surrogate 
marker of plaque inflammation. In a prospective study, Yun et al. were the first researchers to 
report on the association of 18F-FDG uptake in vessels and cardiovascular risk (Yun et al. 
2002). Rudd and colleagues were, however, the first to show uptake of 18F-FDG in 
atherosclerotic lesions in a prospective study published in 2002 (Rudd et al. 2002). Since then, 
the imaging of atherosclerosis with 18F-FDG has been utilized in both human and animal 
studies to image inflammation in atherosclerotic lesions (Rudd et al. 2007; Tarkin et al. 2014; 
Tawakol et al. 2005; Wells et al. 2017). Uptake of 18F-FDG has been shown to correlate with 
lesion macrophages in atherosclerosis in animal models (Wenning et al. 2014; Zhang et al. 
2006). Masteling et al. found that high 18F-FDG activity in carotid plaques was localized to 
areas with macrophage infiltration (Masteling et al. 2011). In a clinical study with 21 patients 
undergoing carotid endarterectomies following 18F-FDG-PET/CTA, the maximum 
standardized uptake value (SUVmax) was associated with increased concentration of CD68, a 
SR (class D) marker expressed on phagocytic cells, mainly macrophages (Menezes et al. 2011). 
A similar finding came from a small study by Tawakol et al., who found that CD68 staining 
was higher in high SUV plaques than in low SUV plaques (Tawakol et al. 2006). Other studies 
have found that FDG uptake is higher in lipid-rich plaques compared with collagen-rich 
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plaques (Silvera et al. 2009). At present, imaging of atherosclerotic plaques utilizing 18F-FDG 
ranges from large scale clinical studies to simple proof of concept studies; for example, the 
effect of statins in lowering 18F-FDG uptake (Tahara et al. 2006; Tawakol et al. 2013; Wu et 
al. 2007) to more thorough investigations, and evaluation in combination with new 
developments of anti-inflammatory therapies (Fayad et al. 2011; Gaztanaga et al. 2015) to gain 
more information about disease pathology. However, since FDG is taken up by cells that are 
metabolically active, it is not a specific marker of inflammation in atherosclerosis and not all 
studies are consistent: some have failed to show uptake of 18F-FDG in atherosclerotic lesions 
(Laurberg et al. 2007) or correlation to macrophages (Myers et al. 2012). There are also 
variabilities depending on several factors such as metabolic state, or imaging time point post 
injection (Bucerius et al. 2014; Huet et al. 2015). High blood glucose levels (>7 mmol/l) can 
also diminish the 18F-FDG uptake in vessels (Bucerius et al. 2014). Other limitations are high 
physiological uptake in the myocardium, limiting the visualization in coronary arteries, which 
to some extent might be possible to suppress by, for example, fasting or low-carbohydrate diets. 
Others have tried to suppress myocardial tracer uptake in preclinical settings by giving 
ketamine/xylazine anesthesia (Nahrendorf et al. 2008). 
 
2.5.4.1 Other PET Tracers 
The research field consists of investigators looking to develop new potential PET tracers and 
the majority has been restricted to testing in cell and animal models (Bucerius et al. 2019; Chen 
et al. 2010; Yang et al. 2018). Others have tried to target different features of the atherosclerotic 
plaque, aside from inflammation, such as hypoxia (Mateo et al. 2014), neoangiogenesis 
markers such as αvβ3 integrin (Beer et al. 2014; Laitinen et al. 2009b; Paeng et al. 2013), and 
microcalcification with sodium fluoride (18F-NaF) (Joshi et al. 2014). Joshi et al. (2014), found 
that imaging with 18F-NaF was more reliable than 18F-FDG in identifying vulnerable coronary 
plaques. These authors also investigated uptake in carotid artery specimens and found that 18F-
NaF uptake occurred at the site of all carotid plaque ruptures and was strongly associated with 
active calcification, macrophage infiltration, apoptosis, and necrosis. In addition, other PET 
tracers, initially used in oncology (DeGrado et al. 2001; Norlen et al. 2018; Sundin 2012), were 
later applied to the vascular imaging of inflammation in atherosclerosis. This included less 
specific macrophage receptor targeting of, for example, translocator protein (TSPO), evaluated 
as a target for macrophage cholesterol efflux (Lecanu et al. 2013; Taylor et al. 2014). It has 
been studied in preclinical settings for aortic plaque imaging (Hellberg et al. 2017; Laitinen et 
al. 2009a) and in a clinical setting for carotid plaque imaging (Gaemperli et al. 2012). Other 
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radiotracers have been evaluated, such as the somatostatin receptor in which 68Ga-DOTATATE 
was correlated with macrophage-rich areas in Apoe-/- mice (Li et al. 2013) and correlated with 
calcification and cardiovascular risk factors in retrospective clinical studies of cancer patients 
(Rominger et al. 2010). Targeting of choline metabolism in macrophages by utilizing choline 
analogues has shown accumulation in macrophage-rich atherosclerotic lesions in preclinical 
studies (Laitinen et al. 2009a; Matter et al. 2006) and in clinical studies (Bucerius et al. 2008). 
 
2.5.4.2 89Zr-based PET Tracer for Imaging of Inflammation in Atherosclerosis 
Besides the radionuclide 18F, other radionuclides have been used to image atherosclerosis with 
PET, such as 68Ga, 64Cu, and 89Zr. The application of more long-lived isotopes, such as the two 
latter, could enable extensive ex vivo evaluation in a preclinical setting compared to 18F. 89Zr 
has been mostly frequently utilized in immuno-PET in the field of oncology (Dilworth et al. 
2018; Fischer et al. 2013; Jauw et al. 2016; Zhang et al. 2011), but there are some recently 
published studies in the field of atherosclerosis (Majmudar et al. 2013; Senders et al. 2018). 
Majmudar et al. (2013) reported promising results and the feasibility of in vivo atherosclerotic 
hybrid PET/MR imaging with an 89Zr-labeled dextran coated nanoparticle as well as high 
uptake by monocytes and macrophages in excised atherosclerotic aortas from Apoe-/- mice. 
Senders et al. (2018) report a novel PET tracer for imaging atherothrombotic burden and plaque 
vulnerability with 89Zr-LA25: a human antibody Fab fragment LA25 binding to advanced 
MDA epitopes, namely malondialdehyde-acetaldehyde (MAA) adducts: OSEs found in human 
atherothrombotic lesions. The authors concluded that 89Zr-LA25 could be a promising PET 
tracer for coronary atherosclerosis imaging given its 2.5-fold higher aorta-to-myocardial uptake 
ratio in diseased animals than the currently approved 18F-FDG. Other PET tracer candidates 
have also been described utilizing 89Zr to monitor leucocyte trafficking in inflammation 
(Fairclough et al. 2016). Molecular probes for targeted imaging in atherosclerosis are 
summarized in Table 2.6. 
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Table 2.6: Molecular imaging probes for the imaging of atherosclerosis.  
Biological events 
 
Molecular 
target 
Imaging 
modalities Imaging Probes 
Species/ 
vessel References 
Vascular 
inflammation, 
endothelial 
activation 
VCAM-1, 
ICAM-1,  
P-Selectin,  
E-Selectin 
CEUS, 
MRI, PET, 
SPECT 
Targeted MBs, 
targeted USPIO,  
18F-, 68Ga-, 99mTc-
labeled-antibodies 
Animals/ 
aorta 
(Broisat et al. 
2014; Kaufmann 
et al. 2007a; 
Kaufmann et al. 
2007b; Li et al. 
2014; Nahrendorf 
et al. 2009; 
Nakamura et al. 
2013)  
Vascular 
permeability Albumin MRI Gadofosveset  
Human/ 
multiple 
vascular beds 
(Phinikaridou et 
al. 2013) 
Macrophage 
receptors 
Scavenger 
receptors 
(SR-A1, 
LOX-1) 
 
MRI,  
SPECT, 
PET 
Targeted USPIO, 
Gd- probes, 99mTc-
labeled antibodies, 
Mal-HSA, 
64Cu/Gd/TAMRA-
Mal-BSA 
 
 
 
Animals/aorta 
 
 
 
 
(Gustafsson et al. 
2006; Jarrett et 
al. 2010; Jarrett 
et al. 2008; Li et 
al. 2010; Segers 
et al. 2013; Wen 
et al. 2014)  
Mannose 
receptor 
 
68Ga-NOTA-
neomannosylated 
human serum 
albumin (MSA), 
18F-FDM 
 
(Kim et al. 2016; 
Tahara et al. 
2014)  
Translocator 
protein 
(TSPO) 
 
11C-PK11195, 18F-
FEMPA 
 
(Hellberg et al. 
2017; Laitinen et 
al. 2009a)  
Somatostatin 
receptor 
68Ga-DOTATATE (Li et al. 2013) 
Leukocyte 
trafficking Leucocytes  
89Zr-Chitosan 
nanoparticles 
 
(Fairclough et al. 
2016) 
Metabolic activity 
Glucose 
metabolism 
 
 
 
 
 
 
 
Phospholipid 
metabolism 
 
PET 
18F-FDG  
 
 
 
 
 
 
 
 
18F-FMCH/11C-
Choline 
 
Humans and 
animals/aorta, 
carotid, 
coronary 
 
 
 
 
 
Animals and 
humans/aorta 
and carotid 
 
(Rudd et al. 
2007; Rudd et al. 
2002; Tarkin et 
al. 2014; 
Tawakol et al. 
2006; Tawakol et 
al. 2005; Zhang 
et al. 2006)  
(Bucerius et al. 
2008; Kato et al. 
2009; Laitinen et 
al. 2010; Matter 
et al. 2006)  
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Neoangiogenesis αvβ3 
MRI, 
SPECT, 
PET 
Gd-labeled RGD 
probes, 18F-labeled 
RGD , 68Ga-labeled 
RGD 
Animals and 
humans/aorta 
and carotid 
(Beer et al. 2014; 
Burtea et al. 
2008; Laitinen et 
al. 2009b; Paeng 
et al. 2013)  
Hypoxia Redox PET 
18F-FMISO (and a 
few other tracers) Animals/aorta 
(Mateo et al. 
2014) 
Microcalcification Bone 
mineralization PET 
18F-NaF Animal/ 
coronary 
(McKenney-
Drake et al. 2018) 
Platelet adhesion, 
atherothrombosis  
GPVI, GP 
IIb/IIIa 
CEUS, 
PET 
Targeted MBs, 
64Cu-labeled 
probes 
Animals/aorta 
and carotid 
(Bigalke et al. 
2013; Guo et al. 
2015; Metzger et 
al. 2015)  
Atherothrombosis 
Von 
Willebrand 
factor,  
Oxidation-
specific 
epitopes 
(OSEs) 
CEUS, 
PET/MRI 
 
Targeted MBs, 
89Zr-LA25 
 
Animals/aorta 
(McCarty et al. 
2010; Senders et 
al. 2018) 
 
2.5.5 Multimodal Imaging 
The combination of imaging modalities for diagnostic purposes can provide synergistic 
advantages over single modalities. The rapidly evolving imaging field has led to the 
development of hybrid imaging, referring to the integration of hardware from two (or more) 
imaging technologies to form a new, more powerful imaging modality. Some examples of 
hybrid imaging modalities are PET/CT, PET/MR, SPECT/CT, and US/MR (Hricak et al. 
2010). The image acquisition can be obtained simultaneously with PET/MR, or sequentially, 
but performed without moving the patient from the bed. The combination of these techniques 
might allow improved characterization of the atherosclerotic plaque. Separately, each of these 
techniques is suitable for imaging of different features of the plaque; stenosis, fibrous cap, 
plaque composition (core), plaque volume with MRI, micro-calcification, inflammation, 
hypoxia, and angiogenesis with PET. Combining PET and MRI in hybrid imaging allows for 
outstanding visualization of the atherosclerotic plaque in combination with detection of 
inflammation. An advantage of hybrid imaging (e.g. PET/CT) is the possibility of obtaining 
attenuation correction of PET data using CT attenuation coefficients. CT scans are, however, 
associated with high radiation doses and combination with MR imaging would limit radiation 
to PET. Combining PET with MRI enables visualization of more plaque components than 
PET/CT (Ripa et al. 2016). 
Hybrid imaging is different from fusion imaging. Fusion imaging refers to two separate 
hardware units where the images have been fused or overlaid by software rather than combined 
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hardware adjustments of positions. Hence the patient or experimental animal undergoes two 
separate scans, not necessarily within a short timeframe. Images from a PET scan can later be 
fused or overlaid with the ones acquired from MRI. Anatomical misalignment, caused by 
differences in patient positioning or respiration, can significantly influence image 
interpretation, resulting in false localization of the imaging probes in atherosclerotic lesions. 
Thus, good software systems for vascular imaging of inflammation are crucial in fusion 
imaging (Giovanella et al. 2010). 
 
2.5.6 Multimodal Probes and Coupling to Biomacromolecules 
The advances in hybrid imaging have created a need for multimodal molecular probes, 
involving a single probe with several incorporated physical features to enable imaging with 
different modalities. This is a rather novel interdisciplinary research field, which has been 
explored more often in the field of cancer research than for CVDs. Multimodal probes may be 
beneficial when studying the pathogenesis of diseases and different properties of imaging 
modalities may be utilized in a single setting (Bucerius et al. 2019; Yang et al. 2018).  
Clinically utilized contrast agents or probes are single modal. More bimode molecular 
imaging probes have been developed for potential clinical use than multimodal probes: the first 
might be more relevant for clinical applications and the second allows for extensive pre-clinical 
evaluation on a research basis. Nahrendorf et al. described a novel trimodal nanoparticle 
consisting of an iron oxide core for MRI and an optically detectable near-infrared fluorochrome 
that is radiolabeled with 64Cu for PET imaging and targeting of macrophage phagocytosis 
(Nahrendorf et al. 2008). In 2006, Gustafsson et al. reported a trimodal macromolecule carrier, 
maleylated bovine serum albumin (Mal-BSA), for the targeting of macrophages, coupled to Gd 
for a signal enhancement in MRI and radiolabeled with 64Cu (Gustafsson et al. 2006). In 2010, 
Jarret et al. applied this probe in an Apoe-/- ligation mouse model in a proof of principle study 
(Jarrett et al. 2010). In addition, Jarrett and Gustafsson reported a similar probe, combining 
64Cu-labeled and magnetic nanoparticles for potential multimodal imaging applications 
(Gustafsson et al. 2006; Jarrett et al. 2010; Jarrett et al. 2008). 
Conjugation to biomacromolecules has been utilized to increase the circulation half-
life of diagnostic or therapeutic agents, one of the most common being albumin (Cao et al. 
2015; Smith et al. 2001). The advantages are due in part to its size (which is above the renal 
threshold), solubility, and in vivo stability. Native albumin specifically interacts with the native 
Fc receptor in a pH-dependent fashion in the endosome and is responsible for recycling 
albumin back into circulation, hence contributing to the long circulatory albumin half-life of 
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19 days. The coupling with albumin can be performed in vitro by covalent binding or by in 
vivo non-covalent coupling (a reversible binding) in which the probe or drug binds albumin in 
the circulation after intravenous injection (Cao et al. 2015; Sleep et al. 2013). Gadofosveset is 
one example of an MRI contrast agent that reversibly binds to human serum albumin (HSA) in 
vivo after injection (Caravan et al. 2002). 
 
In summary, the following goals should be achieved in vascular imaging with molecular 
probes: 
• High specificity to the target: To have a specific tracer or probe with a long enough 
circulating half-life to reach the target site with high uptake in the lesion 
• High binding affinity with the target: To obtain high uptake of the imaging probe in 
target tissue within a limited circulation timeframe requires that the imaging probe has 
binding properties with a fast on-rate (Kon) and slow off-rate (Koff). 
• Choice of the most appropriate radionuclide: This means choosing the ideal 
radionuclide for the target you want to image and matching the half-life of the probe. 
Low positron energy and positron range are favorable physical properties for the 
imaging of small structures such as atheroslcerotic lesions. 
• High contrast ratio: High signal-to-noise ratio (SNR) or contrast-to-noise ratio 
(CNR) as in addition to target-to-background ratio (TBR) to ensure appropriate 
interpretation of the physiological and pathological conditions of the diseases. Hence, 
the remaining radioactivity in the blood pool and the surrounding tissue should be low 
to minimize the background signal. 
• High stability in vivo: Maintenance of the intact structure of an imaging probe is 
important for increasing the likelihood of the probe reaching the target. This is a major 
challenge because numerous enzymes or proteases that are present in serum or targeted 
tissue may degrade the imaging probe. 
• Low immunogenicity and toxicity: To reduce side-effects. 
• Production and economic feasibility: Important for large scale or clinical use. 
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3 AIMS 
The overall aim of this thesis was to develop probes for the molecular imaging of inflammation 
and to evaluate the specificity of the probes under in vitro conditions and their applicability in 
in vivo models of inflammation and atherosclerosis. 
 
The specific aims of each study were: 
I. To evaluate the cellular interaction of polyvinyl alcohol (PVA)-based microbubbles 
(MBs) and the influence of nanoparticle location in the shell. 
II. To investigate whether antibody conjugation of MBs could improve the targeting of 
inflammatory markers and to evaluate this by SPECT/CT fusion imaging in a rat 
inflammation model. 
III. To develop modified human serum albumin (HSA)-based probes for molecular 
targeting of macrophage scavenger receptors, and to evaluate the specificity of the 
probes and their cellular uptake routes. 
IV. To evaluate radiolabeled modified HSA probes and determine their feasibility with 
regard to targeting and visualizing inflammation in atherosclerotic plaques under in 
vivo and ex vivo conditions by molecular imaging in a mouse model of atherosclerosis. 
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4 METHODOLOGICAL CONSIDERATIONS 
4.1 General Study Design 
This thesis project constitutes two MB-based studies (study I and II) and two studies (III and 
IV) on modified HSA-based probes. In study I, the in vitro cellular interaction of non-targeted 
bi-modal MBs with or without superparamagnetic iron oxide nanoparticles (SPIONs) is 
evaluated, and in study II, more advanced multimodal MBs targeting adhesion molecules are 
evaluated. Further, in the second study, cellular interaction and specificity are investigated 
through in vitro experiments, and the in vivo feasibility is evaluated by SPECT/CT imaging in 
a rat model of peritonitis. In study III, the cellular uptake routes and specificity of HSA-based 
probes are evaluated under in vitro conditions. In study IV, these probes are evaluated for 
plaque uptake in an Apoe-/- mouse model of atherosclerosis with the help of fusion imaging 
with PET and MRI as well as extensive ex vivo evaluation of probe uptake in atherosclerotic 
plaques. The overall design of the four studies is presented in Figure 4.1.  
 
Figure 4.1: Summary of the molecular imaging probes and the overall study design.  
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4.2 Probe Development and Evaluation 
4.2.1 Microbubbles (Study I and II) 
The MBs utilized in study I and study II were developed within the scope of the European 
Commission’s 3MiCRON project. Briefly, these MBs were (on average) 3 μm in size, and they 
were based on a previously developed MB with biocompatible synthetic organic PVA material 
(Cavalieri et al. 2005; Cerroni et al. 2011; Paradossi 2010). The MBs were further 
functionalized, within the scope of the 3MiCRON project, for potential MRI by the conjugation 
of SPIONs on the outside of the MBs or by the incorporation of SPIONs in the shell. The 
different types of conjugations between SPIONs and MBs, as well as the physical, magnetic, 
and US imaging properties of these MBs were recently reported (Barrefelt et al. 2014; Brismar 
et al. 2012; Grishenkov et al. 2009). 
In study I, the following different types of MBs were evaluated under in vitro 
conditions for cellular interaction with macrophages and endothelial cells: PVA only (plain), 
MBs with SPIONs on the outside (type A), and MBs with SPIONs incorporated in the shell 
(type B).  
In study II, a similar but more advanced PVA-based MB, with several different layers 
with multimodal properties, was developed in the lab of Lars Dähne (Surflay Nanotec GmbH, 
Germany). Two layers of SPIONs were embedded between the shell layers for MRI; a metal 
chelating ligand (NOTA) layer was used for nuclear imaging; a fluorescent layer, for 
fluorescence microscopy evaluation; and an outmost layer of streptavidin, for conjugation with 
antibodies. These advanced MBs were evaluated for their in vitro targeting properties and 
interaction with macrophages and endothelial cells. The MBs were also evaluated for their 
physical and imaging properties. The physical properties were evaluated using transmission 
electron microscopy and atomic force microscopy, and the imaging properties were evaluated 
based on the US acoustic characteristics and nuclear imaging properties. Nuclear imaging was 
performed in vivo in a rat model of peritonitis. The SPECT and MRI properties of non-targeted 
MBs have been previously reported, and their biodistribution has been evaluated in rats 
(Barrefelt et al. 2013a; Barrefelt et al. 2013b).  
4.2.2 Radiotracers (Study II and IV) 
In study II, 99mTc-labeling was used for imaging with SPECT/CT. Technetium-99m 
pertechnetate (99mTcO4-) was produced in a 99Mo/99mTc-generator on site at the Department of 
Radiopharmacy, Karolinska University Hospital. The procedure for radiolabeling the MBs 
with 99mTc, with NOTA as the chelating ligand, is described in detail in study II. Immediately 
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after radiolabeling, the purification procedure was started with a series of washing steps. 
Labeling efficiency was validated by instant thin-layer chromatography, which yielded ≥95% 
99mTc-labeling. The resulting 99mTc-anti-ICAM-1-labeled MBs were utilized for SPECT/CT 
imaging in vivo.  
In study III and IV, the PET radionuclide 89Zr was generated in a cyclotron, a particle 
accelerator, and delivered by Perkin Elmer (BV Cyclotron VU, Amsterdam, the Netherlands). 
The radiolabeling procedure for HSA-DFO, Mal-HSA-DFO, and Aco-HSA-DFO is described 
in detail in study III and IV. The agents were analyzed and purified using high-performance 
liquid chromatography. The fractions with the highest radio peak were collected and used in 
the experiments. The labeling yield and radiochemical purity of the 89Zr-labeled tracers (89Zr-
HSA, 89Zr-Mal-HSA, and 89Zr-Aco-HSA) were determined by instant thin-layer 
chromatography. In study IV, clinically approved fluorine-18-labeled fluorodeoxyglucose 
(18F-FDG) was produced on site (Department of Radiopharmacy, Karolinska University 
Hospital); it met all the criteria for human use and was applied without further purification. The 
properties of the molecular probes and their target molecules are summarized in Figure 4.2. 
 
Figure 4.2: Molecular probes and their target molecules. Strategies for targeting by surface conjugation with 
specific ligands or antibodies able to bind disease related molecules. 
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4.2.3 Radiosafety 
Nuclear imaging results in ionizing radiation exposure, and it is important for the investigator 
to be well protected and educated about the potential risk of repeated radiation exposure. 
Radiosafety is an important concept when it comes to working with and handling radioactive 
material. Radioactivity cannot be seen or be felt in smaller doses, so safety precautions are 
important for personnel as well as patients. The radiation dose depends on the type of radiation 
(α, β, or γ), duration of the exposure and the distance from the source, and whether the radiation 
shield was used. Both gamma emitters and positron emitters are used in this project. Gamma 
rays are the most penetrative form of radiation. However, the radiation can be shielded with 
lead, and safety precautions to minimize contamination and radiation dosimetry should always 
be applied. The goal is to minimize the radiation dose as much as possible to avoid hazardous 
side effects, as significant radiation exposure is associated with an increased risk of cancer. 
Although the risk from a single scan is low, there could be adverse cumulative effects of 
radiation exposure over a life time.  
 
4.3 Experimental Cells 
It is important to choose relevant cells for your disease model. Immortalized cell lines, which 
proliferate in an uninhibited manner, are usually more easy to culture but different from 
primary isolated cells, which normally only can be cultured until a certain passage before the 
classical markers are lost and their morphology starts to get altered. Expression of adhesion 
molecules by cells in a controlled 2D environment is very different from that in the complex 
3D structures within the body where cells interact physically and chemically with each other 
and the ECM. This must be taken into consideration during the translation of in vitro findings 
into in vivo applications. It is possible that in in vivo settings, the same types of cells behave 
differently or show different expression patterns or morphology. For example, unlike in vitro 
cultured endothelial cells, in vivo endothelial cells are in contact with the basement membrane 
and are constantly exposed to blood flow and shear stress. However, it is possible to obtain 
more complex cell co-cultures on 3D matrices that better mimic the in vivo milieu, for example, 
by utilizing biomaterials such as hydrogels. 
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4.3.1.1 Endothelial Cells 
2D cell cultures from mouse and human cells were used in this thesis to study the in vitro 
cellular interactions of MBs or modified HSA probes. Both commercially available cells and 
primary cells isolated from the rat peritoneum or from human buffy coats were used in the 
studies. In study I, MyEnd+/+ microvascular myocardial endothelial cells were used to study 
the interaction of MBs with endothelial cells. Human umbilical vein endothelial cells 
(HUVECs) are one of the most utilized cell lines to study the function and pathogenesis of 
endothelial cells (Cheung 2007). In study II, HUVECs were incubated with pro-inflammatory 
cytokines in order to induce the upregulation of adhesion molecules (ICAM-1, VCAM-1 and 
E-selectin). The adhesion of MBs to the endothelial cells was assessed during both static and 
flow conditions. Since HUVECs originate from venous vessels, and since atherosclerosis is a 
disease that affects the arterial wall, we also included mouse aortic endothelial cells in study 
II. In study III, HUVECs were used only as a physiological model of ECs.  
 
4.3.1.2 Macrophages 
The RAW264.7 mouse leukemic monocyte macrophage cell line is commonly used to study 
phagocytosis in macrophages in laboratory research. This cell line was originally established 
from the ascites of a tumor induced in a male mouse by intraperitoneal injection of the Abelson 
murine leukemia virus. RAW264.7 cells were utilized in study I to evaluate the non-specific 
adhesion or uptake of non-targeted MBs with or without SPIONs. In study II, peritoneal 
macrophages from a rat peritonitis model were isolated and cultured to evaluate macrophage 
interaction with anti-ICAM-1-labeled MBs. In study III, THP-1 cells, a human monocytic 
leukemia-derived cell line, were differentiated into THP-1 macrophages and also THP-1 foam 
cells to study the cellular interaction of modified HSA probes. Peripheral blood was obtained 
from healthy volunteers, with their written consent, at the Blood Center of Karolinska 
University Hospital, Stockholm, Sweden. The blood monocytes were induced to differentiate 
into macrophages in vitro and further polarized into M1 or M2 macrophages.  
 
4.3.1.3 Vascular Smooth Muscle Cells 
The interaction of human carotid SMCs with modified HSA probes was investigated in study 
III.  
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4.4 Experimental Animal Models 
In vivo rodent models were used for the molecular imaging of inflammation (study II) and 
atherosclerosis (study IV). 
4.4.1 Animal Model of Inflammation (Study II) 
In study II, a rat model of peritonitis was utilized for targeting inflammation in vivo. Peritonitis 
was induced by intraperitoneal injection of Zymozan, which triggers an inflammatory response 
and induces expression of ICAM-1 on inflammatory cells. The targeting of ICAM-1 on 
peritoneal macrophages was evaluated in vivo with SPECT/CT after intravenous injection of 
99mTc-anti-ICAM-1-labeled MBs. Isolated peritoneal macrophages were assessed by flow 
cytometry after incubation with anti-ICAM-1-labeled MBs. Ideally, ex vivo evaluation of 
peritoneal macrophages after intravenous administration of 99mTc-anti-ICAM-1-labeled MBs 
would have provided a more direct evaluation of the in vivo uptake of the probes by these cells.  
4.4.2 Animal Model of Atherosclerosis (Study IV) 
Most atherosclerotic mouse models are based on genetic modifications of the C57BL/6 mouse 
strain (Paigen 1985). In study IV, an Apoe-/- mouse model on the C57BL/6 genetic background 
was utilized. Female mice were used, and the mice were provided a western diet (21% fat, 
0.15% cholesterol) to aggravate disease progression. Female mice are known to develop 
atherosclerosis at an earlier age and are less prone to fight with each other than male mice. 
Ideally, for the purpose of research, animals of both sexes should be included. However, 
examining sex-based differences in the properties and functions of the probes was not within 
the scope of this work. 
 
4.5 Ethical Considerations 
Experimental animals were utilized in study II and IV. We complied with the 3R principle: 
replace, reduce, refine. Good laboratory practices were applied, and institutional and national 
guidelines for the care and use of laboratory animals were followed with the approval of the 
Stockholm Animal Ethics Committee. No human subjects were used in the work of this thesis. 
The development of molecular imaging probes, which are not yet approved for clinical use, 
requires thorough preclinical evaluation in small animals and thereafter in larger animals for 
the assessment of in vivo stability and toxicity profiles, before clinical phase trials are permitted. 
To some extent, in vitro evaluation can be performed to study specificity and cellular uptake 
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routes; however, the in vitro conditions will not satisfactorily simulate the complexity of the in 
vivo state. Therefore, the molecular imaging probes in the present study were also investigated 
using non-invasive techniques in animal models for the evaluation of their biodistribution and 
pharmacokinetic profiles. A strict protocol that was in accordance with the legislations for 
animal studies was followed for determining the injection frequency, injection volume, as well 
as imaging time under anesthesia. The imaging techniques used in this project are non-invasive, 
and they are not known to cause any discomfort to the animal. Biocompatible materials were 
used as the basis of the molecular probes, but they are also considered as foreign material. 
When injected into the bloodstream, these materials may cause immunogenic responses, 
allergic reactions or unwanted side effects. Moreover, the size of the molecular probes would 
affect their biodistribution profile, so in vivo studies in animals are necessary to evaluate these 
components. Rodents are feasible as animal models, as they are easy to handle and are far less 
costly than larger animal models. However, imaging in small animal models may be more 
challenging due to the small size of organs as compared to rabbits or pigs. Especially with 
regard to the vascular imaging of atherosclerosis, the spatial resolution of the small-sized 
vessels is limited to the spatial resolution of the preclinical imaging modality (Razuvaev et al. 
2008), and the specificity and sensitivity of the molecular probes. 
 
4.6 In Vitro Fluorescence Techniques  
4.6.1 Flow Cytometry (Study II, III, and IV) 
Flow cytometry was used to quantify probe adhesion to cell-surface receptors by utilizing the 
fluorescence properties of the MBs in study II, and to quantify the adhesion or uptake of HSA-
based probes by cells in study III and IV. Flow cytometry was also applied to correctly 
characterize isolated cells with specific markers, although no single marker is specific or 
sensitive enough for a certain polarization (Jaguin et al. 2013).  
The working principle of flow cytometry is based on single-cell analysis of 
fluorescently labeled cells conjugated with either antibodies or beads (in our case, a fluorescent 
MB labeled with antibodies or fluorescent HSA-based probes). Fluorescent antibodies or 
molecular probes are incubated with cells in suspension and can be used to stain either surface 
markers or intracellular markers via cell permeabilization protocols. Thereafter, quantitative 
data are acquired in a flow cytometer: different lasers are used to excite the fluorescently 
labeled cell markers and the cells are distinguished based on their size (forward scatter), 
granularity (side scatter) and fluorescence intensity. To account for fluorescence spillover when 
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utilizing several fluorochromes in a staining panel, single staining and fluorescence minus one 
can be applied. To assess antibody specificity, the corresponding isotype control for the 
antibody of interest can be utilized (Adan et al. 2017). Post-processing analysis was performed 
with the FlowJo software, and different gating strategies were applied to evaluate the cell 
populations of interest.  
 
4.6.2 Fluorescence Microscopy (Study I, II, and III)  
Fluorescence microscopy was used to assess in vitro MB- or HSA-based probe−cell 
interactions and uptake in study I, II, and III respectively. Fluorescence microscopy is an 
essential tool for imaging cell morphology and molecule localization. In fluorescence 
microscopy, the whole sample is illuminated by the excitation light. Although the highest 
intensity of excitation light will be at the focal point of the lens, the fluorescence from out-of-
focus points will cause background fluorescence and reduce the sharpness of the images. 
Confocal microscopy is a specialized form of standard fluorescence microscopy that has 
improved optical resolution in the z-axis plane as a result of a reduction in the amount of out-
of-focus light reaching the detector; moreover, serial optical sections can be visualized in a 
thick specimen. In brief, an excitation laser is reflected off a dichroic mirror, as a result of 
which light of shorter wavelengths is reflected and light of longer wavelengths passes through. 
The reflected light hits mirrors that are mounted on motors; this allows the laser to scan across 
the sample and also scan in different planes in a z-stack. The emitted light from the sample 
(with longer wavelength) is scanned by the same mirrors and emitted through the dichroic 
mirror and focused onto a pinhole, and the out-of-focus light is filtered out. The emitted 
fluorescent light is measured by a detector and a photomultiplier tube coupled to a computer, 
which creates a sharp image. Factors that affect the fluorescence signal are the sample 
preparation method, the mounting media used, and the choice of fluorophores. For imaging 
fluorophores in a stained sample, the fluorophores should be excited separately, but this 
increases the scanning time. If possible, separate lasers should be used for exciting the 
fluorophores, and their emission should be evaluated for potential “bleed through” of the signal 
into other detection channels (Hibbs 2004).  
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4.7 In Vivo Molecular Imaging 
4.7.1 SPECT/CT Hybrid Imaging and Quantification (Study II) 
In study II, SPECT was performed in conjunction with CT for anatomical imaging. SPECT 
data were reconstructed using a 3D method (Siemens Flash 3D), and the volume was matched 
to the reconstructed CT volume. Data analyses were performed by an independent investigator, 
who drew volumes of interests around the whole body and each organ on the CT images.   
 
4.7.2 Vascular PET/MR Fusion Imaging and Quantification (Study IV)  
The acquired PET data were processed using MicroPET Manager and evaluated using the 
Inveon Research Workplace software (Siemens Medical Systems, Malvern, PA, USA). MR 
bright-blood images were used to define the anatomy of the vasculature and MR black-blood 
images of the aortic root were acquired to observe the vessel wall of the aortic root. Co-
registration with MR images was done mainly by fitting the PET signal from the liver, vertebral 
column and sternum to the bright-blood MR image. After co-registration, volumes of interest 
were manually drawn around the aortic arch and the blood pool signal in the vena cava. 
There are several methods for the quantification of PET tracer uptake in vascular 
imaging. The two principle quantitative measures of this variable are standardized uptake value 
(SUV) and target-to-background ratio (TBR). SUV is calculated with the following formula: 
(radioactivity in tissue/tissue volume)/(injected radioactivity/body weight). TBR is the ratio of 
SUV in the target tissue (atherosclerotic lesion) to SUV in the background (e.g., blood). The 
maximum and mean TBR and SUV values are also calculated. TBRmax refers to the ratio of 
maximum SUV in the lesion to mean SUV in blood, whereas TBRmean refers to the ratio of 
mean SUV in the lesion to mean SUV in blood. There is some variability in the reported results 
in the literature, depending on the quantification method, the vessel area under analysis 
(whether it is the most diseased part of the vessel or the whole vessel), the timing of imaging 
after radiotracer injection, and the metabolic state. In study IV, we measured both SUVmax and 
TBRmax. 
 
4.7.3 Ex Vivo Evaluation of Radioactive Uptake (Study IV) 
Radiotracer uptake in excised organs after intravenous injection or by cells in vitro after 
incubation was evaluated with a gamma counter (Wallac™ Wizard 3” 1480, Perkin Elmer). 
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Phosphor imaging autoradiography (PI-ARG) was used for visual and quantitative 
measurement of radiotracer uptake in atherosclerotic plaques in study IV. Hand-drawn regions 
of interests with manually applied thresholds or a semi-automatic method for the calculation of 
radiotracer signal in the regions of interest, with one set threshold, were used to evaluate 
radiotracer accumulation in diseased areas of the mouse aorta. The methodological procedure 
is described in detail in study IV. 
 
4.8 Statistical Analysis 
All statistical analyses were conducted using GraphPad Prism (version 7 for Macintosh). 
Assessment of normal distribution with the Shapiro-Wilk normality test, the drawing of 
histograms and q-q plots, and assessment of homogeneity of variance with Levene’s test were 
performed in SPSS (version 24 for Macintosh). If normality and equality of variance were not 
rejected at the significance level of 0.05, the group means were compared using parametric 
tests. For the comparison of two groups, Student’s t-test was applied (study II, III, and IV). 
For the comparison of measurements within the same animal, a paired t-test was applied (study 
II). For comparison of more than two groups, one-way ANOVA was applied (study III and 
IV). In study III, two-way ANOVA was applied when more than two variables existed, and 
linear regression was applied to test relationships. A repeated-measures ANOVA was applied 
in the time-lapse experiments in study III. The post-hoc correction methods used for ANOVA 
were Tukey’s multiple comparison test (study III and IV) or Dunnett’s test (study III). If data 
did not follow a Gaussian distribution, nonparametric tests were applied: the Mann Whitney 
U-test was used for comparisons between two groups (study II). Two-tailed P-values less than 
0.05 were considered to indicate significance. 
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5 RESULTS AND DISCUSSION  
A series of probes have been evaluated in the literature with the aim of increasing the specificity 
of molecular multimodal imaging techniques. In an attempt to develop molecular probes with 
high target specificity for different markers of inflammation in atherosclerosis, we evaluated 
cellular interactions, cellular uptake routes as well as specificity for the in vitro target, and 
imaging feasibility and accumulation at the target site in vivo, within the scope of this thesis. 
 
5.1.1 Cellular Interaction of Non-targeted Molecular Probes 
In order to assess the contribution of non-specific uptake by inflammatory cells, we evaluated 
how cells interact with non-target contrast agents with different physical properties. In study 
I, three different types of MBs were evaluated. The cellular interaction of plain PVA MBs and 
two types of MBs (types A and B) with SPIONs was evaluated by light microscopy and 
confocal laser scanning microscopy (CLSM). Uptake or adhesion of these 3-μm MBs seemed 
to be driven by phagocytosis in RAW264.7 macrophages or low, non-specific weak adherence 
to MyEnd+/+ endothelial cells. Particles larger than 0.5 μm have been known to enter phagocytic 
cells via phagocytic pathways (Champion et al. 2008; Oh et al. 2014). However, non-specific 
uptake via pinocytosis is also a possible route of uptake into the cells. The engulfment pattern 
of the RAW264.7 macrophages was different between the plain, type A and type B MBs. We 
found that SPION-FITC-labeled type A MBs were already localized inside RAW264.7 
macrophages after 30 min, and the uptake by macrophages increased 10-fold after 2 h of 
incubation with the cells, Figure 5.1. Observational and quantitative data obtained using 
CLSM showed that macrophages favored uptake of type A MBs externally coated with 
SPIONs over uptake of type B MBs with the SPIONs embedded inside the polymer shell. These 
results are in line with other published data which have shown that the coating of nanoparticles, 
is an important strategy for increasing biocompatibility and circulation time and for minimizing 
rapid clearance by immune cells in the bloodstream (Shi et al. 2009; Singh et al. 2010; Sosale 
et al. 2015). The plain PVA MBs that were not associated with SPIONs showed the lowest 
uptake by the macrophages. They were first observed in the macrophages only after 6 h of 
incubation, but no adherence or uptake was observed in endothelial cells. Several factors are 
known to influence the uptake of MBs by phagocytic cells such as macrophages and other 
immune cells. MBs with SPIONs on their external surface might induce immunogenic 
responses and are therefore cleared faster (Singh et al. 2010; Sosale et al. 2015), so the presence 
 Results and Discussion 
_________________________________________________________________________________________________________________ 
 
62 
of the nanoparticle on the surface might be an influential factor. Other factors that influence 
the pattern of uptake might be the surface shape, size, and net charge of the particle (Xiao et al. 
2011).  
In study II, we used a polymeric streptavidin-coated MB with SPIONs embedded in 
the shell, and in accordance with the discussion above, we found a low level of engulfment or 
adherence of non-target multimodal MBs to macrophages or endothelial cells. The evaluation 
of cellular uptake was conducted with flow cytometry and CLSM under in vitro conditions. 
Molecular probes, such as MBs, are known to acquire a “protein corona” after exposure to 
serum, which is primarily composed of albumin (Mahmoudi et al. 2011; Wan et al. 2016), a 
known suppressor of phagocytic uptake; this is probably why these MBs are less prone to 
phagocytosis under in vivo conditions. However, hypothetically, this would also affect the 
probability of the probes reaching their target site. Targeting strategies that employ antibodies 
or peptides have been shown to improve the specificity of and to increase the accumulation of 
molecular imaging probes at the target site (Kaufmann et al. 2007a; Kaufmann et al. 2007b; 
Kiessling et al. 2014; Klibanov et al. 2006). Such strategies are important for signal generation 
in imaging applications. 
In study III and IV, we evaluated a considerably smaller type of molecular probe that 
was in the nanosize range (4−10 nm) and consisting of modified HSA. Coupling to 
biomacromolecule carriers is a strategy utilized to increase the circulation half-life of molecular 
probes, so as to increase their chances of reaching the target site (Sleep et al. 2013; Zhang et 
al. 2018). Cellular adhesion or uptake of non-targeted probes by macrophages was low or 
absent in the in vitro study. These results are consistent in flow cytometry, fluorescence 
microscopy and CLSM (study III).  
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Figure 5.1: Results from study I, showing (A) Uptake counted as MBs per cell of plain, types A and B MBs by 
macrophages after 30 min and 2 h incubation. The uptake of MBs by macrophages was monitored in transmission 
mode, and the FITC-labeled MBs were visualized by laser excitation at 488 nm by confocal laser scanning 
microscopy (CLSM). MBs and cells were quantified by counting in five to nine random regions-of-interest (ROIs) 
per sample. To discriminate between internalized and extracellular MBs, the MB suspension was replaced by 
Trypan Blue resulting in the quenching of external MBs, but not internalized MBs. In each ROI 50–300 cells were 
counted. Bars represent the mean and SD. Statistical significance was determined with ANOVA and Tukey´s post 
hoc test, **** P<0.0001. (B) Transmission electron microscopy images of the three different types of MBs; plain 
MBs; type A MBs; and type B MBs. Scale bar represents 500 nm. 
 
5.1.2 Cellular Interaction of the Targeted Molecular Probes 
In molecular imaging, the targeting specificity can be increased by functionalizing probes with 
antibodies, peptides or other chemical modifications. This will result in the accumulation of 
the probes at the target site and improved signal for imaging. In study II, III, and IV, we 
evaluated the specificity of our probes for targeting markers upregulated in inflammation and 
in atherosclerotic lesions. 
 
5.1.2.1 Microbubbles 
In study II, the MBs were further functionalized, within the scope of the European 
Commission’s 3MiCRON project, to improve their multimodal as well as targeting properties. 
The targeting properties of these novel MBs were evaluated for the first time, within the scope 
A) 
B) 
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of this thesis. We found that the labeling of streptavidin-coated MBs with biotinylated 
antibodies was feasible and resulted in high surface density (it was indicated that 47% of the 
MB surface area was covered by antibodies, corresponding to 4900 antibodies/μm2). 
Interestingly, these MBs might be coupled to other biotinylated antibodies or peptides to target 
other disease-specific markers.  
Antibody−antigen interactions are of a reversible non-covalent nature, as they involve 
electrostatic forces, van der Waals forces, hydrogen bonds, and hydrophobic interactions. 
Labeling with monoclonal antibodies would potentially increase target specificity and target 
affinity, which is considered as the strength of the interaction between an epitope and an 
antibody’s antigen-binding site. Monoclonal antibodies were coupled to MBs in study II to 
target adhesion molecules expressed by endothelial cells and peritoneal macrophages. We 
found that adhesion to the activated endothelium was increased up to 6-fold in HUVECs and 
up to 12-fold in mouse aortic endothelial cells as compared to non-targeted MBs (Figure 2, 
study II). Further, evaluation of the MBs by flow cytometry and CLSM was facilitated by the 
physical properties of the shell-fluorescent layer. MBs labeled with monoclonal antibodies 
recognized their target antigens under both static (Figure 4, study II) and flow conditions 
(Figure 5 and 6, study II), with both immobilized antigens and free antigens contained in a 
single cell suspension (Figure 2 and 3, study II). Highlights from CLSM and flow cytometry 
results of VCAM-1 labeled MBs are shown in Figure 5.2. The overall strength of the 
antibody−antigen complex, referred to as “avidity,” was improved by Ab-labeled MBs as 
compared to the non-targeted MBs or the isotype controls, as demonstrated by the almost 
complete clearance of non-specifically bound MBs after the application of high shear stress-
pulse in an in vitro flow set up in study II.  
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Figure 5.2: Results from study II, showing (A) Confocal laser scanning microscopy (CLSM) Z-stack images 
showing HUVECs with attached anti-VCAM1 MBs, and low or no adherence of isotype-control-MBs after flow. 
Images were acquired after 2 min continuous flow at 2 dyn cm-2 followed by wash and a 20 dyn cm-2 pulse. Blue 
staining represents DAPI staining of cell nuclei; red represents Cy3 antibody-labeled MBs; green represents Alexa 
Fluor 488-phalloidin staining of actin. (B) Flow cytometry analysis of anti-VCAM-1-MBs and isotype-control-
MBs incubated with HUVECs in cell suspension under continuous agitation for 1h. Histograms showing increased 
binding of anti-VCAM-1-MBs to cytokine-treated cells; measured as % Cy3 positive cell.  
  
5.1.2.2 Modified HSA Probes 
In addition to the polymeric non-targeted and targeted MBs used in study I and II, chemical 
modification of the biomacromolecule HSA was utilized for targeting macrophages in study 
III and IV. We hypothesized that modified HSA can be taken up by macrophages in 
atherosclerotic lesions, and serve as probes for molecular imaging. Mal-BSA is a known ligand 
of SR-A1, and it has been extensively studied under in vitro and in vivo conditions in relation 
to atherosclerosis (Ben et al. 2015; Goldstein et al. 1979; Greaves et al. 2009; Haberland et al. 
1986a; Haberland et al. 1986b). Recently, radiolabeled Mal-BSA has been proposed as a 
possible radiotracer for the imaging of vascular inflammation in atherosclerosis. However, only 
proof-of-concept studies have been conducted in a small number of Apoe-/- mice (n = 3) at 13 
weeks of age (Jarrett et al. 2010).  
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Here, we hypothesized that HSA would be more suitable for human application, and 
investigated aconityl (Aco) as an alternative chemical modification in addition to maleyl for 
cellular uptake routes and evaluation of specificity in vitro in study III. The modified HSA 
probes Mal-HSA and Aco-HSA were successfully labeled with FITC or 89Zr via a DFO 
chelator. The signaling agents enabled further investigation with flow cytometry, CLSM, real-
time microscopy and gamma counter measurements. An increase of several folds in the cellular 
uptake of these probes was found in comparison to non-modified HSA. The uptake was 
dependent on the concentration of the probes, and the time of incubation. The uptake 
mechanism of these molecular probes was mediated primarily via SR-A1 receptor-mediated 
endocytosis, as demonstrated by silencing, blocking and competition studies as well as co-
staining with lysosomal markers, Figure 5.3 (Figures 4, 8, 5 and 2 respectively, study III). 
Our findings were in line with previously published data on maleylated probes (Gustafsson et 
al. 2015; Gustafsson et al. 2006; Haberland et al. 1986b; Jarrett et al. 2010; Zhang et al. 2018). 
The receptors CD36 and LOX-1 had no or little contribution to receptor-mediated uptake when 
they were silenced. Further, maleyl is covalently bound to HSA, where MalA reacts with an 
amine group on HSA to result in the formation of an amide bond. The interaction of Mal-HSA 
with SR-A1 most probably involves several types of non-covalent interactions that are similar 
to antibody−antigen interactions.   
 
Figure 5.3: Results from study III, showing (A) Confocal laser scanning microscopy (CLSM) Z-stack image 
of THP-1 macrophages with internalized Mal-HSA-FITC probes (green). (B) Images of orthogonal views with 
white cross indicating co-localized (yellow) Mal-HSA-FITC probe (green) and LAMP2 lysosome staining (red-
Alexa Fluor 568) shown in the merged image. DAPI cell nuclei staining (blue).  
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Mal-HSA was shown to be primarily recognized by differentiated THP-1 cells and 
subsets of polarized primary human macrophages, preferably M0 and M2 polarized 
macrophages, under in vitro conditions (Figure 1,3 and 7, study III). However, no or little 
uptake of Mal-HSA by HUVECs or human carotid SMCs was observed (Figure 9, study III). 
The results for FITC-labeled modified HSA probes were consistent with those of flow 
cytometry and CLSM. The results for 89Zr-labeled probes were also in line with those for FITC-
labeled probes. In summary, both types of modified HSA probes (Mal-HSA and Aco-HSA) 
showed specific recognition of SR-A1 primarily on macrophages. This encouraged us to 
investigate the imaging feasibility of our probe as a potential PET radiotracer for the targeting 
of macrophages and atherosclerotic plaques in vivo. 
5.1.3 In Vivo SPECT/CT Hybrid Imaging of Inflammation with Targeted Anti-
ICAM-1-labeled MBs 
To evaluate the feasibility of nuclear imaging with targeted multimodal MBs, a model of rat 
peritonitis was utilized to increase macrophage infiltration and expression of ICAM-1. MBs 
were successfully labeled with 99mTc and further conjugated to anti-ICAM-1 antibodies. A 
detectable two-fold increase in the radiotracer signal was observed in the peritoneal cavity of 
rats with induced peritonitis as compared to the control rats (Figure 8 and 9, study II). 
5.1.4 In Vivo PET/MR Fusion Imaging of Inflammation in Atherosclerosis 
To our knowledge, no large-scale in vivo imaging studies have yet been performed with 89Zr-
radiolabeled Mal-HSA probes targeting macrophages in inflamed atherosclerotic lesions. 
Small-scale proof-of-concept studies with 64Cu-radiolabeled Mal-BSA have been attempted 
through Jarrett et al. (Jarrett et al. 2010). In order to evaluate the feasibility of using the 
radiotracer 89Zr-Mal-HSA for targeting atherosclerotic plaques in Apoe-/- mice, we conducted 
in vivo PET/MR imaging studies, as well as ex vivo studies with non-targeted 89Zr-HSA and 
wild-type mice (C57BL/6) for comparison. In summary, in vivo PET/MRI of the 
atherosclerotic aortic arch showed a 26% increase in SUVmax and a 19% increase in TBRmax in 
Apoe-/- mice at 16 weeks of age as compared to age and diet-matched wild-type mice. 
Representative PET/MRI and MR images are shown in Figure 5.4. The ex vivo quantitative 
analysis corroborated the in vivo PET measurements, and showed significant accumulation of 
the specific radiotracer at target sites with the gamma counter; and similar findings were 
obtained with PI-ARG of excised atherosclerotic aortas in the Apoe-/- mice as compared to the 
control animals. An example of the PI-ARG measurements in an Apoe-/- mouse is shown in 
Figure 5.5. The 89Zr-Mal-HSA radiotracer signal was found in CD68-stained aortic root 
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sections of Apoe-/- mice, but the signal was absent in wild-type mice without macrophage 
staining (indicated by CD68). In contrast, no detectable differences were found between the 
wild-type mice and Apoe-/- mice for the radiotracer 18F-FDG in our experimental set-up. This 
could partly have been the result of a suboptimal imaging time point after the 18F-FDG 
injection. Improved vascular imaging has been reported at 90−180 min after injection of 18F-
FDG (Bucerius et al. 2014). Further, Blomberg et al. showed that quantification was improved, 
as indicated by higher TBRs, when atherosclerotic plaque inflammation was imaged at 180 
min as compared to 90 min after injection of 18F-FDG (Blomberg et al. 2014a); however, such 
improvement was not observed in the quantification of vascular calcification metabolism 
(Blomberg et al. 2014b).  
 
Figure 5.4: Results from study IV, showing (A) Molecular imaging of aortic arch by 89Zr-Mal-HSA. Images 
(transverse plane) from 9.4 T MRI (left panel) and the 1 h dynamic MicroPET scan (right panel) are fused (middle 
panel). Images show accumulation of radiotracer signal from atherosclerotic aortic arch (Aarch) in the Apoe-/- 
mouse, and void of the signal in the wild type (WT) mouse. Image data were processed using MicroPET manager 
and evaluated using the Inveon Research Workplace (IRW) software (Siemens Medical Systems). (B) 9.4 T MRI 
in Apoe-/- mouse utilizing the phenomenon of flow to give rise to different image appearances. Bright blood image 
(coronal plane) of the Aarch and branches with gradient echo sequence (left panel), and black blood image 
(transverse plane) of aortic root, indicated by the red cross, with spin echo sequence (right panel). 
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Blomberg et al. (2014) suggested that the SUVmax of the carotid plaque is the most 
reliable surrogate for plaque vulnerability. However, in another study published by Niccoli 
Asabella et al., the authors argued that the maximum and mean TBR values are more reliable 
than SUV for identifying inflamed plaques (Niccoli Asabella et al. 2014). Hence, there is some 
controversy about these measures, and we have therefore reported both the SUVs and TBRs in 
study IV. 
 
Figure 5.5: Results from study IV, showing aortic arch with branches and thoracic aorta from Apoe-/- mouse. (A) 
Excised aorta, cut open and en face stained with Sudan IV (red color). (B) Corresponding phosphor imaging 
autoradiography of 89Zr-Mal-HSA shows radiotracer signal in plaque area identified by en face staining. 
  
5.2 Strengths and Limitations 
• Nomenclature: Specificity and sensitivity are important concepts in diagnostic 
measurements, but the terminology is utilized differently according to the purpose of 
the study in question. In the case of diagnostic tests, specificity is defined as the ability 
of the test to correctly exclude individuals who do not have a given disease, and it 
determines the rate of true negative results. Diagnostic sensitivity is the ability of a test 
to correctly identify people who have a given disease, and it determines the rate of true 
positive results. Ideally, diagnostic tests should have 100% sensitivity and 100% 
specificity, but this is rarely the case. In molecular imaging, the term “sensitivity” is 
utilized in relation to the detection limit: that is, it is the minimum amount of radiotracer 
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required to provide a detectable signal, which is in the picomolar range in the case of 
PET. Specificity is determined by factors such as probe specificity for the target and 
CNR, among others. An understanding of these concepts is important for the 
development of probes for diagnostic molecular imaging. Within the scope of this 
thesis, we can conclude that probes functionalized with antibodies or chemically 
modified probes showed specificity for the target, as well as increased adherence or 
uptake by cells as compared to non-targeted molecular probes. These results were 
consistent across several different fluorescence techniques performed in vitro. Further, 
when these molecular probes were radiolabeled, they provided detectable signals on 
SPECT and PET; this could mean that they have the potential to improve diagnostic 
accuracy and precision. However, there are some limitations that need to be addressed 
for the sake of future improvement.  
• Toxicity studies: No toxicity studies, in vitro or in vivo, were performed. Cells were 
evaluated visually by microscopy, and the expression of classical markers as well as 
live/dead staining was evaluated by flow cytometry. However, a low toxicity profile 
was assumed in the case of the utilized HSA-modified probes, as a similar BSA-based 
maleylated probe showed low toxicity profiles in fibroblasts (Gustafsson et al. 2006). 
Nonetheless, a thorough investigation of the toxicity profiles and in vivo stability must 
be conducted before any clinical experiments can be undertaken. 
• Power calculation: No power analysis was done to determine the minimal sample size 
for the animal experiments in study II and IV, although pilot studies were conducted 
prior to the imaging studies in study IV.   
• Ex vivo evaluation: In study II, ex vivo evaluation of the injected 99mTc-labeled anti-
ICAM-1-labeled MBs was not performed, for example, by isolating peritoneal 
macrophages for flow cytometry evaluation or gamma counter measurements. In 
addition, it would have been interesting to compare the imaging findings with non-
targeted MBs for the evaluation of in vivo target specificity. 
• Fusion imaging: In study IV, the major drawback was the non-simultaneous PET-MRI 
imaging. The fusion of both imaging modalities was challenging, and a mis-match in 
image alignment that affected the data analysis might have been possible. Moreover, 
misinterpretations of the signal source on account of a partial volume effect might have 
occurred, as a result of which the PET signal may have been under- or over-estimated. 
This is of crucial importance in the imaging of small structures such as atherosclerotic 
plaques. However, imaging with a 9.4 T MR scanner allowed us to obtain detailed 
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images of the aortic arch with high spatial resolution and acceptable SNR. Moreover, 
the ex vivo evaluations supported the in vivo PET findings and validated the in vivo 
quantifications.  
• Comparison with 18F-FDG: In study IV, the time protocols for FDG imaging might 
have contributed to low TBRs, possibly due to a high signal and spill-over effect of the 
surrounding myocardium, and hence, led to underestimation of the PET signal. No 
head-to-head comparison with the same radionuclide was performed. It might have 
been possible to compare Mal-HSA and FDG by coupling 18F to Mal-HSA or, 
theoretically, 89Zr to FDG, but that would not have been feasible. Not utilizing the 
advantage of the long half-life of 89Zr would have limited the ex vivo evaluation due to 
rapid decay of 18F.  
• Off-target distribution: In biodistribution studies, high-intensity liver signals were 
observed. This could be partly explained by SR-A1 expression by the liver sinusoidal 
cells, but it might also be a result of non-specific clearing mechanisms by the liver, a 
common challenge for all intravenously injected compounds in the body. The blocking 
experiments in study IV showed a clear decrease in the liver uptake with a resulting 
increase in the aortic uptake. The challenge for the future would be to decrease the liver 
uptake/clearance of these probes. Unlike 18F-FDG, which is known to be taken up by 
metabolically active cells and tissues and therefore influenced by the metabolic state, 
89Zr-Mal-HSA would not present this problem to the same extent.  
• Radiotracer signal and macrophage content: The macrophage content was not 
determined in study IV, so it was not possible to correlate macrophage accumulation 
to the radiotracer signal. This could be performed by digital quantification of 
immunohistochemistry CD68-positive staining in aortic root sections and 
coregistration with the radiotracer signal on PI-ARG images.  
• Spatial resolution: Spatial resolution is a limitation in studies on small structures. In 
our setting, spatial resolution was affected by several factors, one of which was the 
spatial resolution of the SPECT or PET scanner. The μPET in our setting has an inner 
spatial resolution of approximately 1.2 mm, and SPECT, <8 mm. When small 
structures such as atherosclerotic lesions in mouse aorta, 1 mm (average) in diameter, 
are imaged, the positron range will also determine the diagnostic precision or accuracy 
of the source signal. Although 89Zr is classified as a short-range positron emitter, it has 
a longer average positron range than 18F: 18F = 0.6 (max, 2.4) mm, 89Zr = 1.3 (max, 3.8) 
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mm (Conti et al. 2016). The positron range also influences the overall spatial resolution 
in PET imaging.  
• Choice of radioisotope: We obtained a stable signal already at 1 h after injection of the 
tracer; therefore, we concluded that the long half-life of 89Zr is not necessary for 
imaging evaluation of only the initial probe uptake. However, from a preclinical 
perspective, it is more feasible to use radionuclides with a longer half-life than 18F to 
enable excessive ex vivo evaluation. Another more suitable radionuclide would have 
been 64Cu, but it is difficult to obtain this radionuclide within Europe.  
• Disease model: We tried to select optimal disease models for testing the molecular 
probes of this thesis project. However, no single animal model ideally reflects the 
complexity of the human disease condition. The pharmacokinetic data obtained from 
animal models cannot be directly translated into humans, but at the least, they provide 
valuable indications for future improvements.  
 
5.3 Concluding Remarks on the Development of Molecular Probes 
for Multimodal Imaging 
Polymer-based molecular probes, which were examined in study I and II, have several 
advantages over the commercially available lipid-shelled MBs that are currently used for 
CEUS imaging. The differences were recently reviewed (Hernot et al. 2008; Lentacker 2009): 
polymer-based MBs are more stable and have a longer shelf- and circulation half-life; however, 
both lipid-based and polymer-based MBs can be functionalized for targeting purposes and drug 
loaded for therapeutic purposes. The acoustic, magnetic and imaging properties of MBs in 
study I and II have been evaluated previously (Barrefelt et al. 2013a; Barrefelt et al. 2013b; 
Brismar et al. 2012; Cavalieri et al. 2005; Grishenkov et al. 2009; Poehlmann et al. 2014; 
Sciallero et al. 2016; Sciallero et al. 2013; Yang et al. 2008).  
Similar approaches with dual targeting of US and MRI have been described in the 
literature (Park et al. 2010; Yang et al. 2008). The dual-targeting MB assessed in study I might 
be more relevant for clinical translation if targeting can be improved by further 
functionalization of the shell, preferably by utilizing the type B MB with SPIONs physically 
embedded in the shell to minimize non-specific uptake by phagocytic cells. The multimodal 
MB theoretically allows several imaging applications and evaluation through both in vitro 
fluorescent applications and in vivo imaging applications. The multimodal MBs utilized in 
study II were too stiff to have the optimal acoustic US properties due to their multi-layer 
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structure. However, they might still be applicable from the nuclear imaging perspective or for 
potential drug loading in a preclinical setting. We can conclude that the multimodal MBs 
utilized in study II serves as a prototype and is less likely to have any clinical potential; 
moreover, the excessive multimodal approach might be more relevant for pre-clinical 
evaluation of disease-specific markers.   
In study III and IV, we investigated the targeting and imaging properties of modified 
HSA-based molecular probes. Biomacromolecule carriers such as albumin have proven to be 
beneficial for decreasing toxicity, increasing specificity and in vivo stability as well as 
prolonging circulation half-life, and might therefore show some promise for the development 
of clinical radiotracers in molecular imaging (Sleep et al. 2013; Zhang et al. 2018). However, 
the half-life of diagnostic molecular probes also depends on the endogenous clearance of the 
probe itself and the impact that the coupling of the probe has on the interaction of the albumin 
portion with FcRn, as this can affect the re-circulation of albumin. For instance, 
conformationally modified albumins are cleared more rapidly through the gp18/gp30 system 
than native albumin (Sleep et al. 2013).  
Possible conformational changes during chemical reactions of the targeting moiety of 
the probe must be taken into consideration, as this might affect the targeting specificity. 
Another important factor is also the host system employed to study the pharmacokinetic 
profiles of the albumin−probe complex. In our case, we used rodent models, and therefore, 
cross-species binding of albumin might differ between endogenous and exogenous albumin 
(Cao et al. 2015; Mathias et al. 1995). Andersen et al. showed that HSA bound weakly to mouse 
FcRn, while mouse albumin bound with a 10-fold higher affinity, which means that human 
albumin is re-circulated to a lesser extent than mouse albumin in the mouse model (Andersen 
et al. 2010). Human FcRn is selective in that it only binds IgG from a limited number of species 
(human, bovine and rabbit) (Ober et al. 2001). Despite their differences, both human and bovine 
albumin are utilized as carriers for molecular probes.  
The HSA-based imaging probes were recently reviewed (Cao et al. 2015), as were their 
therapeutic applications (Lee et al. 2015; Zhang et al. 2018). In the case of the HSA-based 
targeting probes, their clinical application is dependent on manufacturing processes for purity 
and the cost aspect. The modified HSA probes employed in study III and IV have potential 
for hybrid imaging with PET/MRI, as was previously demonstrated by Jarret et al. with Mal-
BSA (Jarrett et al. 2010; Jarrett et al. 2008). With HSA as a carrier, it is possible to combine 
imaging techniques such as SPECT, PET and MRI. Multimodal molecular imaging in 
cardiovascular diseases based on nanoprobes conjugated to PET signaling agents was recently 
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reviewed by (Tu et al. 2018). Thus, all the studies so far indicate that HSA is an excellent 
platform for molecular imaging probes and multimodal strategies. 
 
5.4 The Future of Molecular Imaging of Atherosclerosis  
The molecular imaging field has evolved rapidly in the last decade. The technical challenges 
of vascular imaging will require further optimization to improve spatial resolution. With new 
improved dual-imaging approaches, such as US/MRI or PET/MRI, different components of 
plaques can be imaged at the molecular and cellular level. Imaging of inflammation in 
atherosclerosis could help monitor disease progression and shed light on the suitability of 
therapeutic interventions such as newly developed anti-inflammatory drugs. This can also 
create a need for more specific probes in clinical applications. With regard to radiotracer 
developments, the cornerstone of all molecular imaging probes is non-toxicity, in vivo stability 
and sufficient circulation half-life to enable accumulation at the target site. Furthermore, the 
major challenges in the future for the development of molecular imaging probes would be to 
optimize their biodistribution and pharmacokinetic profiles. 
Based on all the new biomarkers identified in atherosclerotic lesions, we could optimize 
molecular probes so that they target clinically relevant and specific biomarkers, and thereby, 
improve the precision and accuracy of targeting. In combination with evolving imaging 
techniques that have improved spatial and temporal resolution, more detailed information about 
plaque vulnerability could be obtained. In the future, the development of molecular imaging 
probes will most probably focus on theranostics approaches and combine diagnostic imaging 
with direct and local treatment at the target site. 
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6 SUMMARY AND CONCLUSIONS  
A total of seven different imaging probes were evaluated in this thesis for the targeting of 
inflammatory markers on endothelial cells and macrophages: four MB-based molecular probes 
and three HSA-based molecular probes.  
The specific conclusions of the thesis are as follows: 
I. SPION modifications of MBs increased cellular uptake by macrophages. 
II. Monoclonal antibody labeling of our novel MBs was feasible and demonstrated 
improved target specificity to adhesion molecules in both static and flow set-ups in 
vitro. 99mTc-labeled anti-ICAM-1-MBs showed detectable signal in the inflamed 
peritoneal area of the rat model in vivo. 
III. The uptake of Mal-HSA and Aco-HSA is primarily receptor-mediated through specific 
binding to SR-A1 on macrophages. Differentiated and polarized macrophages 
recognized the Mal-HSA probe. 
IV. 89Zr-radiolabeling of Mal-HSA probes resulted in detectable signals in atherosclerotic 
lesions in Apoe-/- mice, as demonstrated by PET/MRI. The findings were corroborated 
by ex vivo quantitative measurements with gamma counter and phosphor imaging 
autoradiography. 
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